2024/12/21 更新

写真a

ハラ ノボル
原 昇
HARA Noboru
所属
医歯学総合病院 魚沼地域医療教育センター 特任教授
職名
特任教授
外部リンク

学位

  • 医学博士 ( 2004年3月   新潟大学 )

研究キーワード

  • 腎癌

  • 精巣腫瘍

  • 尿路上皮癌

  • 前立腺癌

研究分野

  • ライフサイエンス / 腫瘍診断、治療学  / 泌尿器腫瘍学

  • ライフサイエンス / 泌尿器科学

経歴(researchmap)

  • 新潟大学医歯学総合病院 講師   Medical and Dental Hospital

    2015年6月 - 現在

      詳細を見る

  • 新潟大学医歯学総合病院 助教   Medical and Dental Hospital

    2006年12月 - 2015年5月

      詳細を見る

  • 新潟県立がんセンター

    2005年4月 - 2006年11月

      詳細を見る

  • 新潟大学病院 医員

    2004年4月 - 2005年3月

      詳細を見る

  • 新潟労災病院

    2002年4月 - 2004年3月

      詳細を見る

  • 長岡赤十字病院

    1996年10月 - 1998年5月

      詳細を見る

  • 武田綜合病院

    1995年4月 - 1995年9月

      詳細を見る

▶ 全件表示

経歴

  • 新潟大学   医歯学総合病院 魚沼地域医療教育センター   特任教授

    2022年4月 - 現在

  • 新潟大学   医歯学総合病院 魚沼地域医療教育センター   特任准教授

    2019年4月 - 2022年3月

  • 新潟大学   医歯学総合病院 泌尿器科   講師

    2015年5月 - 2019年3月

  • 新潟大学   医歯学総合研究科 生体機能調節医学専攻   講師

    2015年5月 - 2019年3月

  • 新潟大学   医歯学総合研究科 医科学専攻   講師

    2015年5月 - 2019年3月

  • 新潟大学   医歯学総合研究科 医科学専攻   助教

    2006年12月 - 2015年4月

  • 新潟大学   医歯学総合病院   助教

    2006年12月 - 2015年4月

  • 新潟大学   医歯学総合研究科 生体機能調節医学専攻   助教

    2006年12月 - 2015年4月

▶ 全件表示

学歴

  • 新潟大学大学院 外科系専攻

    1998年4月 - 2002年3月

      詳細を見る

  • 新潟大学医学部医学科   Faculty of Medicine   School of Medicine

    1989年4月 - 1995年3月

      詳細を見る

取得資格

  • 医師

 

論文

  • A carbon 21 steroidal metabolite from progestin, 20β-hydroxy-5α-dihydroprogesterone, stimulates the androgen receptor in prostate cancer cells. 査読

    Ando T, Nishiyama T, Takizawa I, Miyashiro Y, Hara N, Tomita Y

    The Prostate   78 ( 3 )   222 - 232   2018年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/pros.23460

    Scopus

    PubMed

    researchmap

  • [LEIOMYOSARCOMA OF THE OVARIAN VEIN WITH THE RENAL VEIN INVASION: A CASE REPORT]. 査読

    Nakayama R, Takizawa I, Maruyama R, Kasahara T, Hara N, Saito K, Tomita Y

    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology   108 ( 4 )   210 - 214   2017年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.5980/jpnjurol.108.210

    PubMed

    researchmap

  • A diagnostic marker for superficial urothelial bladder carcinoma: lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progression. 査読 国際誌

    Makoto Kawaguchi, Noboru Hara, Vladimir Bilim, Hiroshi Koike, Mituko Suzuki, Tae-Sun Kim, Nan Gao, Yu Dong, Sheng Zhang, Yuji Fujinawa, Osamu Yamamoto, Hiromi Ito, Yoshihiko Tomita, Yuchi Naruse, Akira Sakamaki, Yoko Ishii, Koichi Tsuneyama, Masaaki Inoue, Johbu Itoh, Masanori Yasuda, Nobuo Sakata, Cha-Gyun Jung, Satoshi Kanazawa, Hiroyasu Akatsu, Hiroshi Minato, Takayuki Nojima, Kiyofumi Asai, Yutaka Miura

    BMC cancer   16 ( 1 )   805 - 805   2016年10月

     詳細を見る

    記述言語:英語  

    BACKGROUND: Pathological stage and grade have limited ability to predict the outcomes of superficial urothelial bladder carcinoma at initial transurethral resection (TUR). AT-motif binding factor 1 (ATBF1) is a tumor suppressive transcription factor that is normally localized to the nucleus but has been detected in the cytoplasm in several cancers. Here, we examined the diagnostic value of the intracellular localization of ATBF1 as a marker for the identification of high risk urothelial bladder carcinoma. METHODS: Seven anti-ATBF1 antibodies were generated to cover the entire ATBF1 sequence. Four human influenza hemagglutinin-derived amino acid sequence-tagged expression vectors with truncated ATBF1 cDNA were constructed to map the functional domains of nuclear localization signals (NLSs) with the consensus sequence KR[X10-12]K. A total of 117 samples from initial TUR of human bladder carcinomas were analyzed. None of the patients had received chemotherapy or radiotherapy before pathological evaluation. RESULTS: ATBF1 nuclear localization was regulated synergistically by three NLSs on ATBF1. The cytoplasmic fragments of ATBF1 lacked NLSs. Patients were divided into two groups according to positive nuclear staining of ATBF1, and significant differences in overall survival (P = 0.021) and intravesical recurrence-free survival (P = 0.013) were detected between ATBF1+ (n = 110) and ATBF1- (n = 7) cases. Multivariate analysis revealed that ATBF1 staining was an independent prognostic factor for intravesical recurrence-free survival after adjusting for cellular grading and pathological staging (P = 0.008). CONCLUSIONS: Cleavage of ATBF1 leads to the cytoplasmic localization of ATBF1 fragments and downregulates nuclear ATBF1. Alterations in the subcellular localization of ATBF1 due to fragmentation of the protein are related to the malignant character of urothelial carcinoma. Pathological evaluation using anti-ATBF1 antibodies enabled the identification of highly malignant cases that had been overlooked at initial TUR. Nuclear localization of ATBF1 indicates better prognosis of urothelial carcinoma.

    DOI: 10.1186/s12885-016-2845-5

    PubMed

    researchmap

  • Dihydrotestosterone synthesis pathways from inactive androgen 5α-androstane-3β,17β-diol in prostate cancer cells: Inhibition of intratumoural 3β-hydroxysteroid dehydrogenase activities by abiraterone. 査読

    Ando T, Nishiyama T, Takizawa I, Ishizaki F, Miyashiro Y, Takeda K, Hara N, Tomita Y

    Scientific reports   6   32198   2016年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/srep32198

    Web of Science

    PubMed

    researchmap

  • Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen 査読

    Keisuke Takeda, Noboru Hara, Tsutomu Nishiyama, Masayuki Tasaki, Fumio Ishizaki, Yoshihiko Tomita

    BMC CANCER   16   332   2016年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMED CENTRAL LTD  

    Background: Recruitment of cofactors in the interaction of the androgen receptor (AR) and AR ligands plays a critical role in determining androgenic/antiandrogenic effects of the AR ligand on signaling, but the functions of key cofactors, including nuclear receptor coactivator (NCOA), remain poorly understood in prostate cancer cells treated with AR ligands.
    Methods: We examined prostate cancer cell lines LNCaP and VCaP expressing mutated and wild-type ARs, respectively, to clarify the significance of NCOAs in the effect of antiandrogens. Hydroxyflutamide showed antagonistic activity against VCaP and an agonistic effect on LNCaP. Bicalutamide served as an antagonist for both. We analyzed mRNA transcription and protein expression of NCOAs in these cells pretreated with dihydrotestosterone and thereafter treated with the mentioned antiandrogens. Transcriptional silencing of candidate NCOAs and AR was performed using small interfering RNA (siRNA). Cell proliferation was evaluated with MTT assay.
    Results: LNCaP treated with bicalutamide showed an about four-fold increase in the expression of NCOA2 mRNA compared to those pretreated with dihydrotestosterone alone (P < 0.01). In VCaP pretreated with dihydrotestosterone, transcriptions of NCOA2 and NCOA7 were slightly increased with bicalutamide (1.96- and 2. 42-fold, respectively) and hydroxyflutamide (1.33-fold in both). With Western blotting, the expression of NCOA2 protein also increased in LNCaP cells treated with bicalutamide compared with that in control cells pretreated with dihydrotestosterone alone. Following silencing with siRNA for NCOA2, PSA levels in media with LNCaP receiving bicalutamide were elevated compared with those in non-silencing controls (101.6 +/- 4.2 vs. 87.8 +/- 1.4 ng/mL, respectively, P = 0.0495). In LNCaP cells treated with dihydrotestosterone and bicalutamide, NCOA2-silencing was associated with a higher proliferation activity compared with non-silencing control and AR-silencing.
    Conclusion: NCOA2, which has been thought to be recruited as a coactivator, possibly plays a corepressive role in AR of prostate cancer cells when treated with antiandrogens, suggesting its potential as a therapeutic target.

    DOI: 10.1186/s12885-016-2378-y

    Web of Science

    PubMed

    researchmap

  • Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes 査読

    Kazuhiro Kobayashi, Toshihiro Saito, Yasuo Kitamura, Vladimir Bilim, Tomotaka Toba, Takashi Kawasaki, Noboru Hara, Toshiki Tanikawa, Yoshihiko Tomita

    INTERNATIONAL JOURNAL OF UROLOGY   23 ( 2 )   153 - 158   2016年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    ObjectivesTo determine the effect of preoperative chemotherapy on survival in patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes.
    MethodsWe retrospectively analyzed 55 consecutive patients who received radical nephroureterectomy with or without preoperative chemotherapy for upper urinary tract urothelial carcinoma clinically involving regional lymph nodes at a single institution between January 1991 and December 2013.
    ResultsMedian follow up was 18 months (range 2-193). Of 55 patients, 24 (43.6%) received preoperative chemotherapy (study group) and 31 (56.4%) underwent primary surgery (control group). Preoperative chemotherapy consisted of two to four cycles (median 3) of cisplatin-containing regimens. The fraction of patients with lower pathological T stage and N stage than clinical T stage and N stage was higher in the study group (29.2% and 54.2%) compared with the control group (3.2% and 16.1%; P = 0.013 and 0.010, respectively). The 5-year overall survival rate was significantly higher in the study group than in the control group (44.0% vs 12.9%, log-rank, P = 0.003). In multivariate analysis incorporating age at diagnosis, Eastern Cooperative Oncology Group Performance Status, clinical N stage and the number of removed lymph nodes, preoperative chemotherapy was a predictor of better overall survival (P = 0.047, HR 0.47, 95% CI 0.22-0.99).
    ConclusionsPreoperative chemotherapy might provide better survival outcomes in patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes.

    DOI: 10.1111/iju.13010

    Web of Science

    PubMed

    researchmap

  • Clinicopathological features and outcomes in patients with late recurrence of renal cell carcinoma after radical surgery 査読

    Kazuhiro Kobayashi, Toshihiro Saito, Yasuo Kitamura, Vladimir Bilim, Tomotaka Toba, Takashi Kawasaki, Noboru Hara, Toshiki Tanikawa, Yoshihiko Tomita

    INTERNATIONAL JOURNAL OF UROLOGY   23 ( 2 )   132 - 137   2016年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    ObjectivesTo characterize patients experiencing late recurrence after primary radical surgery for renal cell carcinoma and to approach the mechanism of late recurrence.
    MethodsWe retrospectively analyzed 657 consecutive patients who underwent radical surgery for pathologically confirmed stage III renal cell carcinoma in a single institution between January 1981 and December 2008. Early or late recurrence was defined as a recurrence occurring before or after 60 months after primary surgery.
    ResultsOf 657 patients, 96 (14.6%) experienced early recurrence, and 41 (6.2%) developed late recurrence. Patients with late recurrence had smaller diameter of primary tumor (median 5 cm vs 8 cm, P < 0.001), lower pathological stage (P < 0.001) and lower nuclear grade (P = 0.004) at primary surgery than those with early recurrence. On multivariate analysis, vascular invasion (including microscopic and gross invasion) was the predictor of late recurrence (P < 0.01, HR 3.79). Overall survival and disease-specific survival after recurrence were longer in patients with late recurrence (median 64 and 76 months, respectively) than in those with early recurrence (34.5 and 35 months, respectively; P = 0.008 and 0.002).
    ConclusionsThese results suggest that micrometastasis at the time of surgery associated with vascular invasion at primary tumor site and their relatively lower malignant potential could lead to late recurrence. Further studies are warranted for better understanding and managing late recurrence of renal cell carcinoma.

    DOI: 10.1111/iju.12996

    Web of Science

    PubMed

    researchmap

  • Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study 査読

    Jalal Hejazi, Reza Rastmanesh, Forough-Azam Taleban, Seyed-Hadi Molana, Ehsan Hejazi, Golamreza Ehtejab, Noboru Hara

    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL   68 ( 1 )   77 - 85   2016年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD  

    Curcumin is an antioxidant agent with both radiosensitizing and radioprotective properties. The aim of the present study was to evaluate the effect of curcumin supplementation on oxidative status of patients with prostate cancer who undergo radiotherapy. Forty patients treated with radiotherapy for prostate cancer were randomized to the curcumin (CG, n = 20) or placebo group (PG, n = 20). They received curcumin (total 3 g/day) or placebo during external-beam radiation therapy of up to 74 Gy. Plasma total antioxidant capacity (TAC) and activity of superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx) were measured at baseline and 3 mo after radiotherapy completion. Analysis of covariance was used to compare the variables between groups following the intervention. Serum PSA levels and MRI/MRS images were investigated. In CG, TAC significantly increased (P < 0.001) and the activity of SOD decreased (P = 0.018) after radiotherapy compared with those at baseline. In CG, however, the activity of SOD had a significant reduction (P = 0.026) and TAC had a significant increase (P = 0.014) compared with those in PG. PSA levels were reduced to below 0.2 ng/ml in both groups, 3 mo after treatment, however, no significant differences were observed between the 2 groups regarding treatment outcomes.

    DOI: 10.1080/01635581.2016.1115527

    Web of Science

    PubMed

    researchmap

  • Retroperitoneal disorders associated with IgG4-related autoimmune pancreatitis 査読

    Noboru Hara, Makoto Kawaguchi, Keisuke Takeda, Yoh Zen

    WORLD JOURNAL OF GASTROENTEROLOGY   20 ( 44 )   16550 - 16558   2014年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BAISHIDENG PUBLISHING GROUP INC  

    IgG4-related autoimmune pancreatitis is frequently accompanied by relevant lesions in the genitourinary tract and retroperitoneal organs, which cause various clinical problems, ranging from non-specific back pain or bladder outlet obstruction to renal failure. The diagnosis of IgG4-related retroperitoneal fibrosis requires a multidisciplinary approach, including serological tests, histological examination, imaging analysis, and susceptibility to steroid therapy. Radiological examinations are helpful to diagnose this condition, but surgical resection is occasionally unavoidable to exclude malignancy, particularly for patients with isolated retroperitoneal involvement. Steroid therapy is the treatment of choice for this condition, the same as for other manifestations of IgG4-related disease. For patients with severe ureteral obstruction, additional ureteral stenting needs to be considered prior to steroid therapy to preserve the renal function. Some papers have suggested that IgG4-related disease can affect male reproductive organs including the prostate and testis. IgG4-related prostatitis usually causes lower urinary tract symptoms, such as dysuria and pollakisuria. Patients sometimes state that corticosteroids given for IgG4-related disease at other sites relieve their lower urinary tract symptoms, which leads us to suspect prostatic involvement in this condition. Because of the limited number of publications available, further studies are warranted to better characterize IgG4-related disease in male reproductive organs. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

    DOI: 10.3748/wjg.v20.i44.16550

    Web of Science

    PubMed

    researchmap

  • Type 2 Diabetes: A Protective Factor for Prostate Cancer? An Overview of Proposed Mechanisms 査読

    Reza Rastmanesh, Jalal Hejazi, Francesco Marotta, Noboru Hara

    CLINICAL GENITOURINARY CANCER   12 ( 3 )   143 - 148   2014年6月

     詳細を見る

    記述言語:英語   出版者・発行元:CIG MEDIA GROUP, LP  

    Diabetes mellitus and prostate cancer are 2 of the most important public health concerns, especially in the elderly population. Although diabetes has been recognized as a potent risk factor for many types of cancers, there is a large amount of evidence that shows that it has a protective role against prostate cancer. The underlying cause of this protective role is not fully understood, however, some mechanisms have been proposed in this area. In the present study we have reviewed these mechanisms and some new mechanisms are also proposed.

    DOI: 10.1016/j.clgc.2014.01.001

    Web of Science

    PubMed

    researchmap

  • Effect of the time from the presentation of symptoms to medical consultation on primary tumor size and survival in patients with testicular cancer: Shift in the last 2 decades 査読

    Kazuhiro Kobayashi, Toshihiro Saito, Yasuo Kitamura, Tomohiro Nobushita, Takashi Kawasaki, Noboru Hara, Kota Takahashi

    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS   32 ( 1 )   43.e17 - 22   2014年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE INC  

    Objectives: To clarify the effect of the time from the presentation of symptoms to medical consultation (time to consultation) on oncological outcomes in men with testicular cancer and to examine whether the recent improvement of delays in consultation has led to better outcomes.
    Methods: We reviewed 175 consecutive patients registered for testicular cancer (124 men with seminoma and 51 men with nonseminoma) at a single institution between 1991 and 2010.
    Results: Men with the time to consultation of >6 months (n = 56) had a poorer overall survival than those with the time to consultation of <= 6 months (log-rank test, P = 0.028), despite similar disease stage between them (P = 0.897) and less prevalent nonseminoma in the former (P = 0.032). Although the negative effect of consultation delay on overall survival was significant only in nonseminoma histology (log-rank test, P = 0.004), the time to consultation of >6 months was an independent risk factor associated with poorer overall survival (hazard ratio [HR] = 18.0, 95% confidence interval [CI]: 1.78 182, P = 0.014), in addition to nonseminoma histology (HR = 17.4, 95% Cl: 1.38-219, P = 0.027) and stage II or higher disease (HR = 12.9, 95% CI: 1.36-123, P = 0.026) in all the patients. The time to consultation was positively correlated with the primary tumor size (P < 0.001). The time to consultation was shorter and the primary tumor size was seemingly smaller in patients registered between 2001 and 2010 (n = 104) than in those registered between 1991 and 2000 (median 74 d vs. 109 d, P = 0.042 and 5.8 +/- 2.6 cm vs. 6.7 +/- 3.3 cm, P = 0.068, respectively), although disease stage and overall survival were not different between the 2 periods (P = 0.233 and log-rank test, P = 0.719, respectively).
    Conclusions: The time to consultation and primary tumor size showed a strong positive correlation in men with testicular cancer. Delays in consultation had a negative effect on their survival, particularly in those with nonseminoma. The time to consultation significantly shortened and the primary tumor size was reduced with a borderline significance in men registered between 2001 and 2010 compared with those between 1991 and 2000, although stage migration or survival improvement in recent years was not observed. (C) 2014 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.urolonc.2013.05.007

    Web of Science

    PubMed

    researchmap

  • Androgen Metabolic Pathway Involved in Current and Emerging Treatment for Men with Castration Resistant Prostate Cancer: Intraprostatic Androgens as Therapeutic Targets and Endocrinological Biomarkers 査読

    Noboru Hara, Tsutomu Nishiyama

    CURRENT DRUG TARGETS   15 ( 13 )   1215 - 1224   2014年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BENTHAM SCIENCE PUBL LTD  

    Androgen and androgen receptor (AR) play a critical role in the development of prostate cancer. Androgen deprivation therapy (ADT) has become the therapeutic mainstay for patients with metastatic prostate cancer. ADT can reduce the serum testosterone level from the normal range between 500 and 600 ng/dl to the castrate level. Following surgical castration, the serum testosterone level decreases to less than 20 ng/dL (0.69 nmol/L) in about three quarters of the patients. Although insufficient suppressions of the serum testosterone level following ADT have not been well recognized to date, the failure in achieving the castrate level of testosterone may have an adverse impact on survival in men with prostate cancer. Although circulating testosterone levels following castration do not necessarily reflect the amount of intraprostatic testosterone or dihydrotestosterone, testosterone during ADT mainly derives from intratumorally synthesized precursors and adrenal androgens. The advent of new agents represented by abiraterone acetate and enzalutamide, which target adrenal or intraprostatic androgen biosynthesis and AR signaling, respectively, has retrieved interest in testosterone levels during ADT. We critically reviewed androgen metabolism and its significance in prostate cancer biology and treatment to promote their better understanding and management of men with prostate cancer.

    Web of Science

    PubMed

    researchmap

  • Lower urinary tract symptoms in patients with Niigata Minamata disease: A case-control study 50 years after methyl mercury pollution 査読

    Noboru Hara, Hisashi Saito, Kota Takahashi, Masayuki Takeda

    INTERNATIONAL JOURNAL OF UROLOGY   20 ( 6 )   610 - 615   2013年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    Objectives To clarify the prevalence of lower urinary tract symptoms and overactive bladder in patients with chronic methyl mercury poisoning. Methods A total of 151 patients (61 men and 90 women; mean age 72.1 years) with Niigata Minamata disease were enrolled. An age- and sex-matched group of 150 participants was used as control. Patients reported their International Prostate Symptom Score and overactive bladder symptom score. Results In men, the total, storage and voiding International Prostate Symptom Score scores were higher in the Niigata Minamata disease group than in the control group (10.6 +/- 7.8 vs 5.0 +/- 5.0, 4.5 +/- 3.3 vs 2.4 +/- 2.4 and 6.1 +/- 5.1 vs 2.7 +/- 3.1, respectively, P<0.001 in all). In women, these scores were also higher in the Niigata Minamata disease group than in the control group (8.9 +/- 7.3 vs 4.0 +/- 4.0, 4.4 +/- 3.2 vs 2.8 +/- 2.4 and 4.5 +/- 5.0 vs 1.3 +/- 2.0, respectively, P<0.001 in all). The prevalence of overactive bladder was more frequent in the Niigata Minamata disease group compared with that in the control group (51.7% vs 26.7%, P<0.001). In both men and women, the overactive bladder symptom score was higher in the Niigata Minamata disease group than in the control group (4.1 +/- 3.0 vs 2.4 +/- 2.9, P=0.002 and 4.6 +/- 3.6 vs 2.7 +/- 2.9, P<0.001, respectively). The International Prostate Symptom Score and overactive bladder symptom score in the Niigata Minamata disease group were highest in patients aged 60-69 years (P<0.001 in both), whereas these increased in an age-dependent manner in the control group. Conclusions Lower urinary tract symptoms and overactive bladder are severe and highly prevalent conditions among patients with methyl mercury poisoning. The higher prevalence of lower urinary tract symptoms among patients aged 60-69 years might be related to the fact that they were exposed to methyl mercury during their childhood/development.

    DOI: 10.1111/iju.12001

    Web of Science

    PubMed

    researchmap

  • Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: Pathological risk factors for relapse and feasibility of surveillance after orchiectomy 査読

    Kazuhiro Kobayashi, Toshihiro Saito, Yasuo Kitamura, Tomohiro Nobushita, Takashi Kawasaki, Noboru Hara, Kota Takahashi

    Diagnostic Pathology   8 ( 1 )   57   2013年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Surveillance after orchiectomy has recently been a management option in patients with stage I seminoma, while it remains controversial in those with stage I nonseminoma, and the risk factor associated with relapse is still a matter of concern in both entities. This study was performed to explore pathological risk factors for post-orchiectomy relapse in patients with stage I seminoma and nonseminoma, and to assess oncological outcomes in those managed with surveillance. Methods: In this single institution study, 118 and 40 consecutive patients with stage I seminoma and nonseminoma were reviewed, respectively. Of the 118 patients with stage I seminoma, 56 and one received adjuvant radiotherapy and chemotherapy, respectively, and 61 were managed with surveillance. Of the 40 men with stage I nonseminoma, 4 underwent adjuvant chemotherapy and 36 were managed with surveillance. Results: No patient had cause-specific death during the mean observation period of 104 and 99 months in men with seminoma and nonseminoma, respectively. In men with stage I seminoma, 1 (1.7%) receiving radiotherapy and 4 (6.6%) men managed with surveillance had disease relapse
    the 10-year relapse-free survival (RFS) rate was 93.4% in men managed with surveillance, and their RFS was not different from that in patients receiving adjuvant radiotherapy (logrank P=0.15). Patients with tunica albuginea involvement showed a poorer RFS than those without (10-year RFS rate 80.0% vs. 94.1%), although the difference was of borderline significance (P=0.09). In men with stage I nonseminoma, 9 (22.5%) patients experienced relapse. Patients with lymphovascular invasion seemingly had a poorer RFS than those without
    40.0% and 18.7% of the patients with and without lymphovascular invasion had disease relapse, respectively, although the difference was not significant (logrank P=0.17). Conclusion: In both men with stage I seminoma and nonseminoma, surveillance after orchiectomy is a feasible option. However, disease extension through tunica albuginea might be a factor associated with disease relapse in patients with organ-confined seminoma, and those with stage I nonseminoma showing lymphovascular invasion may possibly be at high risk for disease relapse. © 2013 Kobayashi et al.
    licensee BioMed Central Ltd.

    DOI: 10.1186/1746-1596-8-57

    Scopus

    PubMed

    researchmap

  • Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer 査読

    Fumio Ishizaki, Tsutomu Nishiyama, Takashi Kawasaki, Yoshimichi Miyashiro, Noboru Hara, Itsuhiro Takizawa, Makoto Naito, Kota Takahashi

    SCIENTIFIC REPORTS   3   1528   2013年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    Intratumoral synthesis of dihydrotestosterone(DHT) from precursors cannot completely explain the castration resistance of prostate cancer. We showed that DHT was intratumorally synthesized from the inactive androgen metabolites 5 alpha-androstane-3 alpha/beta, 17 beta-diol(3 alpha/beta-diol) in prostate cancer cells via different pathways in a concentration-dependent manner. Additionally, long-term culture in androgen-deprived media increased transcriptomic expression of 17 beta-hydroxysteroid dehydrogenase type 6(HSD17B6), a key enzyme of oxidative 3 alpha-HSD that catalyzes the conversion of 3 alpha-diol to DHT in prostate cancer cells. Correspondingly, the score for HSD17B6 in tissues of 42 prostate cancer patients undergoing androgen deprivation therapy(ADT) was about 2-fold higher than that in tissues of 100 untreated individuals. In men receiving ADT, patients showing biochemical progression had a higher HSD17B6 score than those without progression. These results suggested that 3 alpha/beta-diol also represent potential precursors of DHT, and the back conversion of DHT from androgen derivatives can be a promising target for combination hormone therapy.

    DOI: 10.1038/srep01528

    Web of Science

    PubMed

    researchmap

  • Retroperitoneoscopic donor nephrectomy with a gel-sealed hand-assist access device 査読

    Kei Arai, Tsutomu Nishiyama, Noboru Hara, Takashi Kasahara, Kazuhide Saito, Kota Takahashi

    BMC UROLOGY   13   7   2013年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMED CENTRAL LTD  

    Background: The hand-assisted technique enables the rapid extraction of the graft, shortening the warm ischemia time (WIT), and the retroperitoneoscopic approach is potentially associated with a less incidence of postoperative ileus in donor nephrectomy for living kidney transplantation. The aim of this study was to assess the efficacy and safety of retroperitoneoscopic donor nephrectomy with a gel-sealed hand-assist access device (GelPort), which is a wound sealing device that permits the access of the hand to the surgical field, free trocar site choice within it, and rapid conversion to open surgery if necessary, while preserving the pneumoperitoneum/pneumoretroperitoneum.
    Methods: Seventy-five consecutive donors receiving this procedure were retrospectively studied. A 2-cm skin incision was made at the midpoint between the tip of the 12th rib and superior border of the iliac bone in the midaxillary line, through which retroperitoneal space was made. Preperitoneal wound with a 6 - 7-cm pararectal incision in the upper abdominal region was connected to the retroperitoneal space. A GelPort was put inside the pararectal surgical wound. The principle was pure retroperitoneoscopic surgery; hand-assist was applied for retraction of the kidney in the renal vessel control and graft extraction.
    Results: The mean operation time including waiting time for recipient preparation was 242.2 +/- 37.0 (range: 214.0-409.0) min, and the mean amount of blood loss was 164.3 +/- 146.6 (range: 10.0-1020.0) ml. The mean WIT was 2.8 +/- 1.0 (range: 1.0-6.0) min. The shortage of renal vessels or ureter was observed in none of the grafts. No donor experienced blood transfusion, open conversion, or injury of other organs. Blood loss was greater in patients with body mass index (BMI) of 25 kg/m(2) or higher than in those with BMI of <25 kg/m(2) (218.4 +/- 98.8 vs. 154.8 +/- 152.1 ml, P=0.031). No donor had postoperative ileus or reported wound pain leading to decreased activity of daily life or wound cosmetic problem.
    Conclusions: Retroperitoneoscopic hand-assisted donor nephrectomy with the mentioned approach was suggested to be a feasible option without compromising safety, although further improvement in surgical techniques is warranted.

    DOI: 10.1186/1471-2490-13-7

    Web of Science

    PubMed

    researchmap

  • Decrease in Lean Body Mass in Men With Prostate Cancer Receiving Androgen Deprivation Therapy: Mechanism and Biomarkers 査読

    Noboru Hara, Fumio Ishizaki, Toshihiro Saito, Tsutomu Nishiyama, Takashi Kawasaki, Kota Takahashi

    UROLOGY   81 ( 2 )   376 - 380   2013年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE INC  

    OBJECTIVE To elucidate the mechanism of the androgen deprivation therapy (ADT)-related decrease in lean body mass (LBM).
    MATERIALS AND METHODS The LBM and blood samples were studied before and after 6 months of ADT in 72 patients with localized prostate cancer. The LBM was assessed using a foot-to-foot bioelectrical impedance analyzer.
    RESULTS Before ADT, the LBM correlated with none of the serum sex steroid levels; however, it correlated closely with serum 5 alpha-androstane-3 alpha, 17 beta-diol glucuronide (Spearman's rank correlation coefficient = 0.409, P = .001) and insulin-like growth factor-1 (IGF-I, Spearman's rank correlation coefficient = 0.329, P = .005). After ADT, the LBM decreased by 0.9% (P = .036), and the serum testosterone and dihydrotestosterone had decreased by 96.8% and 94.3%, respectively (P < .001 for both), and the IGF-I had increased by 11.6% (from 19.9 to 22.2 nmol/L, P = .001). The serum 1,25-dihydroxyvitamin D3 [1,25(OH)2D] levels decreased after ADT by 9.8% (from 66.2 to 59.7 pg/mL, P = .008), and the post-treatment LBM correlated inversely with 1,25(OH) 2D (Spearman's rank correlation coefficient = -0.343, P = .003). The post-treatment LBM was dissociated with 5 alpha-androstane-3 alpha, 17 beta-diol glucuronide and IGF-I. The pretreatment and post-treatment LBMs both correlated inversely with serum sex hormone-binding globulin (P = .024 and P = .016, respectively).
    CONCLUSION The deficiency in androgen levels was suggested to be a link to the ADT-related decrease in LBM; the androgen metabolite 5 alpha-androstane-3 alpha, 17 beta-diol glucuronide has a potential value for assessing the LBM in untreated men. IGF-I also promotes muscle building and is positively regulated during ADT. Sex hormone-binding globulin possibly accelerates the ADT-related decrease in LBM. Although the mechanism for the decrease in 1,25(OH) 2D and its inverse correlation with LBM during ADT is unclear, 1,25(OH) 2D might be a biomarker reflecting the ADT-related decrease in LBM. UROLOGY 81: 376-380, 2013. (C) 2013 Elsevier Inc.

    DOI: 10.1016/j.urology.2012.10.050

    Web of Science

    PubMed

    researchmap

  • The RENAL Nephrometry Score and the PADUA Classification for the Prediction of Perioperative Outcomes in Patients Receiving Nephron-Sparing Surgery: Feasible Tools to Predict Intraoperative Conversion to Nephrectomy 査読

    Kazuhiro Kobayashi, Toshihiro Saito, Yasuo Kitamura, Tomohiro Nobushita, Takashi Kawasaki, Noboru Hara, Kota Takahashi

    UROLOGIA INTERNATIONALIS   91 ( 3 )   261 - 268   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:KARGER  

    Objective:To evaluate the potential of the RENAL nephrometry score and the PADUA classification in the prediction of perioperative outcomes represented by intraoperative conversion to nephrectomy in patients with renal tumors for which nephron-sparing surgery (NSS) was attempted. Methods: Recent 100 open NSSs attempted for cT1 renal tumors at a single institution were studied retrospectively. Results: With the RENAL, the operation time and ischemia time were longer in the high complexity group (p = 0.01 and p = 0.03, respectively), and blood loss was seemingly greater in this group (394 vs. 220 and 167 ml, p = 0.09). Conversion to nephrectomy was more frequent in the high complexity (4 procedures, 33.3%) than in the low (0%) and moderate (1 procedures, 1.5%) groups (p < 0.01). Regarding the PADUA, the operation time, blood loss and ischemia time increased according to the complexity (p = 0.04, p = 0.02, and p = 0.02, respectively). Conversion to nephrectomy was more frequent in the high complexity (4 procedures, 22.2%) than in the low (0%) and moderate (1 procedure, 1.8%) groups (p < 0.01). In patients with achieved NSS, postoperative estimated glomerular filtration rate was more impaired in the high complexity group in the PADUA (p = 0.02), although not significant in the RENAL (p = 0.11). Conclusions: Both the RENAL and PADUA are useful in the prediction of conversion to nephrectomy in addition to NSS-associated perioperative outcomes. (C) 2013 S. Karger AG, Basel

    DOI: 10.1159/000353086

    Web of Science

    PubMed

    researchmap

  • The role of naftopidil in the management of benign prostatic hyperplasia 査読

    Noboru Hara, Takaki Mizusawa, Kenji Obara, Kota Takahashi

    Therapeutic Advances in Urology   5 ( 2 )   111 - 119   2013年

     詳細を見る

    記述言語:英語  

    Naftopidil, which to a certain extent shows an affinity to α1D-adrenoceptor subtype in addition to a high affinity to α1A-adrenoceptor, has been used for the treatment of benign prostatic obstruction and benign prostatic hyperplasia (BPH) associated lower urinary tract symptoms (LUTS). The aim of the present review is to systematically refer to the published studies on this unique agent for BPH. Based on a randomized prazosin-controlled study and another double-blind placebo-controlled study, which verified the dose-dependent effects of naftopidil, the Japanese Ministry of Health, Labor and Welfare approved naftopidil for treating men with BPH in 1996. Several tamsulosin-controlled studies have suggested treatment effects of naftopidil similar to those of tamsulosin and potentially higher efficacy for alleviating storage symptoms by naftopidil. Although well-designed, randomized studies are warranted to confirm the long-term outcomes and effector/target of naftopidil, the α1A-antagonist naftopidil, which also blocks α1D-adrenoceptor, improves voiding symptoms, and may also be useful for the management of men with storage symptoms represented by nocturia, retrieving their quality of life impaired by BPH-associated LUTS. © 2012, SAGE Publications. All rights reserved.

    DOI: 10.1177/1756287212461681

    Scopus

    PubMed

    researchmap

  • Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer 査読

    Noboru Hara, Itsuhiro Takizawa, Etsuko Isahaya, Tsutomu Nishiyama, Tatsuhiko Hoshii, Fumio Ishizaki, Kota Takahashi

    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS   30 ( 5 )   596 - 601   2012年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE INC  

    Background: Luteinizing hormone (LH) during androgen-deprivation therapy (ADT) with gonadotropin-releasing hormone analogues (GnRHa) has been thought to be biologically inactive, and the regulation of LH during ADT with GnRHa is thus unknown. Insulin-like growth factor-1 (IGF-1) is involved in the regulation of cell proliferation and differentiation, and IGF-1 production in the liver is dependent on growth hormone (GH) secretion from the anterior pituitary. Despite the presence of IGF-1 receptors in the gonadotroph, associations between the GH/IGF-1 and pituitary-gonadal axes, e.g., whether IGF-1 elicits the LH secretion, remain unclear.
    Methods: Seventy-one patients with localized prostate cancer, who received ADT with GnRHa, were prospectively studied based on their blood samples before treatment and after ADT for 6 months. We employed highly sensitive assays for measurement of serum testosterone (electrochemiluminescence immunoassay), GH/IGF-1 (radioimmunoassay), adrenocorticotropic hormone (ACTH: immunoradiometric assay), LH (chemiluminescent immunoassay), and dehydroepiandrosterone sulfate (DHEA-S: chemiluminescent enzyme immunoassay).
    Results: No correlation was noted between the pretreatment LH and IGF-1 levels; after ADT, the serum LH level was closely correlated with the IGF-1 concentration [Spearman's correlation coefficient (rs) = 0.370, P = 0.001]. The serum levels of androgens and gonadotropins reduced following ADT (P < 0.001 in all). The serum IGF-1 level increased (22 +/- 6 nmol/L) compared with that at the baseline (19 +/- 5 nmol/L) (P < 0.001), but no change was observed in the serum GH concentration between before and after ADT (1.4 +/- 2.3 vs. 0.9 +/- 0.9 mu g/L, respectively, P = 0.691). The serum testosterone level was not correlated with the LH level either before or after ADT. The testosterone and DHEA-S levels after ADT were correlated with ACTH concentration (rs = 0.367, P = 0.002 and rs = 0.354, P = 0.002, respectively). We did not identify any correlations between the serum IGF-1 concentration and Gleason score, PSA value, or androgen levels.
    Conclusions: During ADT with GnRHa, IGF-1 possibly promotes LH production, although its role is unclear. Associations among pituitary-gonadal, pituitary-adrenal, and GH/IGF-1 axes represented by IGF-1-mediated LH secretion and ACTH-mediated androgen synthesis are of interest, since both prostate epithelium proliferation and male anabolic activity are involved in these 3 axes. Assessment of oncologic outcomes is warranted for their significance in patients with prostate cancer. (C) 2012 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.urolonc.2010.11.001

    Web of Science

    PubMed

    researchmap

  • Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy 査読

    Shuichi Komatsu, Noboru Hara, Fumio Ishizaki, Tsutomu Nishiyama, Itsuhiro Takizawa, Etsuko Isahaya, Takashi Kawasaki, Kota Takahashi

    PROSTATE   72 ( 11 )   1207 - 1213   2012年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    BACKGROUND Interleukin-6 produced in adipose tissue plays a role in lipid metabolism, and also interacts with sex steroids. This study was performed to elucidate the mechanism of lipid metabolism disorder during androgen deprivation therapy (ADT) in terms of the association of interleukin-6 with sex steroids. METHODS Seventy-two patients with localized prostate cancer were prospectively studied based on their body-composition and blood samples before and after ADT for 6 months. RESULTS Before ADT, serum interleukin-6 levels were inversely correlated with serum total-testosterone (rs?=?-0.305, P?=?0.009) and dihydrotestosterone (rs?=?-0.380, P?=?0.006) concentrations, but not correlated with adrenal androgen or estradiol levels. Pretreatment interleukin-6 levels were positively correlated with %body fat (rs?=?0.349, P?=?0.003) and %visceral fat (rs?=?0.384, P?=?0.001). After ADT, %body fat increased (P?<?0.001) and lean body mass decreased (P?=?0.036). After ADT, in contrast to the pretreatment relationship, interleukin-6 levels were positively correlated with total-testosterone concentrations (rs?=?0.343, P?=?0.003), and were positively correlated also with levels of androstenedione (rs?=?0.351, P?=?0.002) and estoradiol (rs?=?0.335, P?=?0.004). Interleukin-6 levels were equivalent between before and after ADT (2.02 vs. 2.16?pg/ml, P?=?0.205), but the positive correlation between interleukin-6 levels and %body or %visceral fat noted before ADT disappeared after ADT. CONCLUSIONS Posttreatment interleukin-6 levels had a strong positive correlation with total-testosterone, androstenedione, and estradiol levels, suggesting that a regulation loop may emerge between these sex steroids and interleukin-6 during ADT. The altered association between interleukin-6 and sex steroids is possibly involved in ADT-related lipid metabolism disorder with unchanged interleukin-6 levels despite increased %body fat. Prostate 72:12071213, 2012. (C) 2011 Wiley Periodicals, Inc.

    DOI: 10.1002/pros.22471

    Web of Science

    PubMed

    researchmap

  • Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer 査読

    Fumio Ishizaki, Noboru Hara, Itsuhiro Takizawa, Tsutomu Nishiyama, Etsuko Isahaya, Takashi Kawasaki, Kota Takahashi

    GROWTH HORMONE & IGF RESEARCH   22 ( 3-4 )   122 - 128   2012年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:CHURCHILL LIVINGSTONE  

    Objective: This study was performed to elucidate the mechanism of high bone turnover during androgen deprivation therapy (ADT) in terms of osteogenic endocrine activity by testosterone, adrenal androgens, and insulin-like growth factor-1 (IGF-I), and to identify markers reflecting the bone mineral density (BMD) during ADT.
    Design: BMD and samples of blood and urine were studied before and after 6 months of ADT in 70 patients with localized prostate cancer.
    Results: Before ADT, serum free-testosterone, dehydroepiandrosterone sulfate (DHEA-S), androstenedione, and IGF-I levels were correlated with BMD (rs = 0.344, p = 0.004; rs = 0.264, p = 0.027; rs = 0.329, p = 0.005; rs = 0.300, p = 0.012, respectively). The serum IGF-I level was independently correlated with the pretreatment BMD (Multivariate p = 0.001). These relationships disappeared after ADT (p = 0.519, 0.316, 0.116, and 0.597, respectively). After ADT, serum levels of free-testosterone decreased (7.9 to 0.2 pg/mL), and DHEA-S and androstenedione were also reduced (3.6 to 2.3 mu mol/L and 5.6 to 2.9 nmol/L, respectively) (p<0.001 in all). In contrast, IGF-I levels were elevated after ADT by 11.6% (19.9 to 22.3 nmol/L, p<0.001). Delta-values of IGF-I (post- minus pretreatment levels, mean: +2.2, ranged between -7.1 and +15.3) were inversely correlated with the pretreatment (rs = -0.333 p = 0.005) and post-treatment (rs = -0.408, p = 0.001) BMD. After ADT, the serum IGF-I level was closely correlated with the serum level of the bone formation marker bone-specific alkaline phosphatase (BAP) (rs = 0.328, p = 0.006), and delta-IGF-I and delta-BAP showed a close positive correlation.(rs = 0.388, p = 0.001). The post-treatment BMD was correlated only with the urine deoxypyridinoline (DPD) concentration (rs = -0.302, p = 0.024) among the bone formation/resorption markers including serum/urine N-telopeptide.
    Conclusions: Serum IGF-I levels increased during ADT in men with a low BMD. Coupled with reduced androgen levels, elevated IGF-I levels, which were positively correlated with BAP during ADT, possibly explain the mechanism of ADT-related high bone turnover. The increase of IGF-I is more prominent in men whose BMD is already low at the baseline, and urine DPD might be a marker that reflects BMD during ADT. (C) 2012 Elsevier Ltd. All rights reserved.

    DOI: 10.1016/j.ghir.2012.04.003

    Web of Science

    PubMed

    researchmap

  • Prediction of pathological and oncological outcomes based on extended prostate biopsy results in patients with prostate cancer receiving radical prostatectomy: a single institution study 査読

    Fumio Ishizaki, Noboru Hara, Hiroshi Koike, Makoto Kawaguchi, Akira Tadokoro, Itsuhiro Takizawa, Tsutomu Nishiyama, Kota Takahashi, Rudolf Hohenfellner

    DIAGNOSTIC PATHOLOGY   7   68   2012年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMED CENTRAL LTD  

    Background: The prediction of pathological outcomes prior to surgery remains a challenging problem for the appropriate surgical indication of prostate cancer. This study was performed to identify preoperative values predictive of pathological and oncological outcomes based on standardized extended prostate biopsies with core histological results diagrammed/mapped in patients receiving radical prostatectomy for prostate cancer clinically diagnosed as localized or locally advanced disease.
    Methods: In 124 patients with clinically localized or locally advanced prostate cancer (cT1c-cT3a) without prior treatment, pathological outcomes on the surgical specimen including seminal vesicle involvement (SVI), positive surgical margin (PSM), and perineural invasion (PNI) were studied in comparison with clinical parameters based on the results of 14-core prostate biopsies comprising sextant, laterally-directed sextant, and bilateral transition zone (TZ) sampling.
    Results: Concerning the association of pathological outcomes with oncological outcomes, patients with PSM and PNI on surgical specimens had poorer biochemical-progression-free survival than those without PSM (logrank p = 0.002) and PNI (p = 0.003); it was also poorer concerning SVI, although the difference was not significant (p = 0.120). Concerning the impact of clinical parameters on these pathological outcomes, positive TZ and multiple positive biopsy cores in the prostatic middle were independent values predictive of SVI with multivariate analyses (p = 0.020 and p = 0.025, respectively); both positive TZ and multiple positive prostatic middle biopsies were associated with larger tumor volume (p<0.001 in both). The percentage of positive biopsy cores (%positive cores) and biopsy Gleason score were independent values predictive of PSM (p=0.001) and PNI (p=0.001), respectively. Multiple positive cores in the prostatic base were associated with proximal/bladder-side PSM (p<0.001), and also linked to poorer biochemical-progression-free survival (p=0.004). Clinical T stage had no association with these pathological outcomes.
    Conclusions: %positive cores and Gleason score in extended biopsies were independent values predictive of PSM and PNI in prostate cancer clinically diagnosed as localized or locally advanced disease, respectively, which were associated with poorer oncological outcomes. When diagramming biopsy-core results, extended biopsy may provide additional information for predicting oncological and pathological outcomes including SVI in patients clinically diagnosed as having localized or locally advanced disease.

    DOI: 10.1186/1746-1596-7-68

    Web of Science

    PubMed

    researchmap

  • Prostate Carcinogenesis with Diabetes and Androgen-Deprivation- Therapy-Related Diabetes: An Update 査読

    Noboru Hara

    EXPERIMENTAL DIABETES RESEARCH   2012   801610   2012年

     詳細を見る

    記述言語:英語   出版者・発行元:HINDAWI PUBLISHING CORPORATION  

    Prostate cancer and the androgen deprivation therapy (ADT) thereof are involved in diabetes in terms of diabetes-associated carcinogenesis and ADT-related metabolic disorder, respectively. The aim of this study is to systematically review relevant literature. About 218,000 men are estimated to be newly diagnosed with prostate cancer every year in the United States. Approximately 10% of them are still found with metastasis, and in addition to them, about 30% of patients with nonmetastatic prostate cancer recently experience ADT. Population-based studies have shown that dissimilar to other malignancies, type 2 diabetes is associated with a lower incidence of prostate cancer, whereas recent large cohort studies have reported the association of diabetes with advanced high-grade prostate cancer. Although the reason for the lower prevalence of prostate cancer among diabetic men remains unknown, the lower serum testosterone and PSA levels in them can account for the increased risk of advanced disease at diagnosis. Meanwhile, insulin resistance already appears in 25-60% of the patients 3 months after the introduction of ADT, and long-term ADT leads to a higher incidence of diabetes (reported hazard ratio of 1.28-1.44). Although the possible relevance of cytokines such as II-6 and TNF-alpha to ADT-related diabetes has been suggested, its mechanism is poorly understood.

    DOI: 10.1155/2012/801610

    Web of Science

    PubMed

    researchmap

  • External Validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese Patients Receiving Radical Prostatectomy 査読

    Fumio Ishizaki, Md. Aminul Hoque, Tsutomu Nishiyama, Takashi Kawasaki, Takashi Kasahara, Noboru Hara, Itsuhiro Takizawa, Toshihiro Saito, Yasuo Kitamura, Kohei Akazawa, Kota Takahashi

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   41 ( 11 )   1259 - 1264   2011年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OXFORD UNIV PRESS  

    Objective: In 2005, the University of California, San Francisco developed the Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score as a new risk stratification tool. The UCSF-CAPRA, which ranges from 0 to 10 points, consists of five clinical variables, prostate-specific antigen, Gleason score, T stage, percent of positive biopsies and age. The aim of this study was to validate the UCSF-CAPRA score for Japanese prostate cancer patients receiving radical prostatectomy using the contemporary Gleason grading.
    Methods: From 1999 to 2010, 211 men who underwent radical prostatectomy were used for validation. Biochemical progression-free survival was calculated using the Kaplan-Meier method and the UCSF-CAPRA and D'Amico risk categories were compared using the log-rank method. The concordance index (c-index) for the UCSF-CAPRA and D'Amico risk classification was calculated.
    Results: Using the UCSF-CAPRA score, 85 (40.3%), 106 (50.2%) and 20 (9.5%) subjects were stratified as 0-2 points (low risk), 3-5 points (intermediate risk) and 6-10 points (high risk). Using the D'Amico risk criteria, 66 (31.3%), 89 (42.2%) and 56 (26.5%) were stratified as low-, intermediate- and high-risk groups, respectively. The Kaplan-Meier analysis showed that the UCSF-CAPRA divided the patients significantly into each risk category. There was no significant difference between low and intermediate in the D'Amico risk classification. The c-index of the UCSF-CAPRA and D'Amico classification was 0.755 and 0.713, respectively.
    Conclusion: The UCSF-CAPRA is an acceptable risk category tool comparable to that of the D'Amico risk classification for Japanese prostate cancer patients receiving radical prostatectomy in the contemporary Gleason grading era.

    DOI: 10.1093/jjco/hyr136

    Web of Science

    PubMed

    researchmap

  • Nephrectomy Plus Endoscopy-Assisted Intussusception Ureterectomy for Patients with Renal Pelvic Cancer: Long-Term Oncologic Outcomes in Comparison with Nephroureterectomy Plus Bladder Cuff Removal 査読

    Noboru Hara, Yasuo Kitamura, Toshihiro Saito, Shunji Wakatsuki, Yasunosuke Sakata, Shuichi Komatsubara

    JOURNAL OF ENDOUROLOGY   25 ( 4 )   691 - 697   2011年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:MARY ANN LIEBERT, INC  

    Purpose: To assess long-term oncologic outcomes in patients with renal pelvic cancer who are receiving nephrectomy plus endoscopy-assisted intussusception ureterectomy. There has been no large study reporting long-term oncologic outcomes of this approach in comparison with those of conventional nephroureterectomy plus bladder cuff removal.
    Patients and Methods: We reviewed 181 consecutive patients with renal pelvic cancer who underwent open nephroureterectomy with complete bladder cuff removal (cuff removal group, n = 33), nephroureterectomy with incomplete cuff removal (orifice-remaining group, n = 39), and nephrectomy with intussusception ureterectomy (intussusception group, n = 109).
    Results: Patients in the intussusception group had larger tumor size, higher histologic grade, and more advanced pathologic stage (P = 0.005, 0.021, and 0.030, respectively), while the incidence of coexistent bladder/ureteral cancer was lower in this group (P < 0.001). The mean operative time was shorter in the intussusception group than in the cuff removal and orifice-remaining groups (201.2 +/- 33.1 and 221.5 +/- 47.2 min, respectively, P < 0.001). The 5-year extraurinary tract recurrence-free survival rate in the intussusception and cuff removal groups was 74.8% and 71.4%, respectively (log-rank P = 0.766), and it was lower in the orifice-remaining group compared with that in the intussusception group (P = 0.031). The 5-year urinary tract recurrence-free survival rate in the intussusception, cuff removal, and orifice-remaining groups was 76.6%, 65.0%, and 65.0%, respectively (intussusception vs cuff removal: P = 0.089). With both univariate and multivariate analyses, intussusception ureterectomy had no significant impact on urinary tract recurrence (multivariate P = 0.553, hazard ratio = 0.784).
    Conclusions: Nephrectomy plus endoscopy-assisted intussusception ureterectomy is an oncologically safe alternative for renal pelvic cancer patients, which is possibly associated with less patient morbidity.

    DOI: 10.1089/end.2010.0336

    Web of Science

    PubMed

    researchmap

  • Kattan postoperative nomogram for renal cell carcinoma: Predictive accuracy in a Japanese population 査読

    Kazuya Suzuki, Tsutomu Nishiyama, Noboru Hara, Kohei Akazawa, Kota Takahashi

    INTERNATIONAL JOURNAL OF UROLOGY   18 ( 3 )   194 - 199   2011年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    Objectives:
    The aim of the current study was to establish the predictive accuracy of the Kattan postoperative nomogram for non-metastatic renal cell carcinoma (RCC) in a Japanese population.
    Methods:
    A total of 211 patients with stage T1-3N0M0 clear cell RCC who underwent radical nephrectomy or nephron-sparing surgery between 1991 and 2004 were included in this analysis. Median follow up was 81 months (range: 4-208). Univariate and multivariate analyses were performed, and the influence of age, sex, clinical presentation, T stage, histological tumor size, grade, and microvascular invasion on disease recurrence-free survival (RFS) was determined. For each patient, the prognostic score for 5-year RFS was calculated using the Kattan nomogram. The discriminating ability of this model was assessed by the concordance index, and bootstrapping was used to evaluate confidence intervals.
    Results:
    The 5-year RFS rate for all patients calculated using the Kaplan-Meier method was 80.6%. In multivariate analysis, the statistically significant prognostic factors for 5-year RFS were high-grade tumors (P = 0.019) and symptomatic disease (P = 0.017). The concordance index for RFS predicted by the Kattan nomogram was 0.735 (95% confidence interval: 0.734-0.736). There was a slight discrepancy between the RFS predicted by the Kattan nomogram and the likelihood of being recurrence-free at 5 years according to the Cox analysis in the current patient population.
    Conclusion:
    These findings suggest the necessity of constructing a more useful nomogram for predicting the prognosis of Japanese patients with non-metastatic RCC.

    DOI: 10.1111/j.1442-2042.2010.02693.x

    Web of Science

    PubMed

    researchmap

  • Clinical feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms: A prospective study 査読

    Noboru Hara, Takaki Mizusawa, Kenji Obara, Etsuko Isahaya, Yuki Nakagawa, Kota Takahashi

    Advances in Urology   2011   804583   2011年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Objectives. To examine the feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms (LUTSs). Methods. Based on the IPSS, men reporting LUTS were prospectively studied using 50mg/day of naftopidil for the first 4 weeks
    satisfied patients continued its 50mg/day (n=11), and those reporting unsatisfactory improvement received its 75mg/day (n=35) for the next 4 weeks. Results. The 75mg group showed improvement in the total IPSS and QOL score in a dose-dependent manner (at 4 weeks: P&lt
    .001, at 4 weeks versus 8 weeks: P&lt
    .05). In the 50mg group, both scores reduced at 4 weeks, thereafter unchanged. The baseline slow stream score alone was higher in the 75mg group (P=.013). The rate of change in the QOL score during the initial 4 weeks (ΔQOL) and Δnocturia was smaller in the 75mg group (P&lt
    .05). Conclusions. Men with high slow stream score and unsatisfactory improvement in nocturia may benefit from dose escalation of naftopidil. Copyright © 2011 Takaki Mizusawa et al.

    DOI: 10.1155/2011/804583

    Scopus

    PubMed

    researchmap

  • Adrenocorticotropic Hormone is Involved in Regulation of Androgen Synthesis in Men Receiving Androgen Deprivation Therapy for Localized Prostate Cancer 査読

    Itsuhiro Takizawa, Noboru Hara, Tsutomu Nishiyama, Etsuko Isahaya, Tatsuhiko Hoshii, Kota Takahashi

    JOURNAL OF UROLOGY   184 ( 5 )   1971 - 1976   2010年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE INC  

    Purpose: We elucidated the regulatory mechanism of adrenal androgen synthesis and examined the influence of pituitary-adrenal axis activity on prostate specific antigen during androgen deprivation therapy.
    Materials and Methods: A total of 72 patients with localized prostate cancer were prospectively studied based on blood samples before and after androgen deprivation therapy for 6 months. Serum pituitary hormones, androgens and prostate specific antigen were measured using highly sensitive assays. Results: After androgen deprivation therapy serum levels of luteinizing hormone, follicle-stimulating hormone, testosterone, dehydroepiandrosterone sulfate, androstenedione and prostate specific antigen decreased compared with those at the baseline (all values p <0.001). No difference was noted between serum levels before and after androgen deprivation therapy in growth hormone (p = 0.098) and adrenocorticotropic hormone (p <0.101). Each serum level of luteinizing hormone, follicle-stimulating hormone and growth hormone after androgen deprivation therapy was not correlated with the serum levels of androgens or prostate specific antigen. The serum adrenocorticotropic hormone level after androgen deprivation therapy was correlated with the serum levels of testosterone (p = 0.002), dehydroepiandrosterone sulfate (p = 0.002), androstenedione (p = 0.006) and prostate specific antigen (p <0.001). Serum dehydroepiandrosterone sulfate and androstenedione levels were also correlated with serum prostate specific antigen (p <0.001 and p = 0.002, respectively).
    Conclusions: In patients treated with androgen deprivation therapy the pituitary-adrenal axis mediated by adrenocorticotropic hormone has a central role in the regulation of androgen synthesis. Serum adrenocorticotropic hormone and adrenal androgen concentrations were correlated with the posttreatment prostate specific antigen. Adrenocorticotropic hormone mediated androgen synthesis is a potential target for advanced androgen deprivation therapy.

    DOI: 10.1016/j.juro.2010.06.115

    Web of Science

    PubMed

    researchmap

  • Trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells. 査読

    Takizawa I, Nishiyama T, Hara N, Hoshii T, Ishizaki F, Miyashiro Y, Takahashi K

    Cancer letters   297 ( 2 )   226 - 230   2010年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.canlet.2010.05.015

    Web of Science

    PubMed

    researchmap

  • Serum Prostate-Specific Antigen Levels Reflect the Androgen Milieu in Patients With Localized Prostate Cancer Receiving Androgen Deprivation Therapy: Tumor Malignant Potential and Androgen Milieu 査読

    Itsuhiro Takizawa, Tsutomu Nishiyama, Noboru Hara, Etsuko Isahaya, Tatsuhiko Hoshii, Kota Takahashi

    PROSTATE   70 ( 13 )   1395 - 1401   2010年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-LISS  

    BACKGROUND. Although androgen deprivation therapy (ADT) has a marked impact on the androgen milieu in vivo and outcomes of prostate cancer (PCa), it remains unclear which parameters reflect the androgen milieu during ADT or whether the milieu is associated with PCa aggressiveness.
    METHODS. Seventy-two patients with localized PCa were prospectively studied based on their blood samples before and after ADT for 6 months. Serum androgens and related values were measured.
    RESULTS. Before ADT, there was no correlation between the serum prostate-specific antigen (PSA) and androgen levels. After ADT, the serum PSA levels were correlated with each level of serum testosterone, dihydrotestosterone, and rostenedione, dehydroepiandrosterone-sulfate (DHEA-S), and 3alpha-diol C (P < 0.010 in all). Before ADT, patients with Gleason score of >= 8 were likely to have lower serum testosterone levels than those with Gleason score of <= 6 (P = 0.058). After ADT, conversely, the testosterone levels in patients with Gleason score of >= 8 appeared to be higher than in those with Gleason score of <= 6 (P = 0.060). The serum DHEA-S level was correlated with Gleason score before and after ADT (P = 0.050 and P = 0.040, respectively).
    CONCLUSIONS. The serum PSA levels well reflect the androgen milieu in localized PCa patients receiving ADT, which can be explained by the Saturation Model and disease control. The androgen milieu in men with high Gleason score PCa is probably less affected by conventional ADT than that in men with low score cancer, which was suggested to be associated with adrenal androgen levels. Prostate 70: 1395-1401, 2010. (C) 2010 Wiley-Liss, Inc.

    DOI: 10.1002/pros.21174

    Web of Science

    PubMed

    researchmap

  • Efficacy of Clean Intermittent Catheterization for Urinary Incontinence in Children with Neurogenic Bladder Dysfunction Secondary to Myelodysplasia 査読

    Kenji Obara, Takaki Mizusawa, Etsuko Isahaya, Kazuya Suzuki, Noboru Hara, Kota Takahashi

    LUTS-LOWER URINARY TRACT SYMPTOMS   2 ( 2 )   100 - 105   2010年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    Objectives: To evaluate the efficacy of clean intermittent catheterization for urinary incontinence in myelodysplastic children.
    Methods: The cohort comprised of 38 children (19 boys and 19 girls, aged between 10 months to 16 years) with neurogenic bladder secondary to myelodysplasia. Group A included 16 children who had dilated upper urinary tract or vesicoureteral reflux when clean intermittent catheterization was introduced. The remaining 22 children with normal upper urinary tract were enrolled to group B. In the present study, we defined socially acceptable continence as having completely dry or slight stress incontinence that patients can manage with several small pads.
    Results: Of the 16 group A patients, 9 obtained socially acceptable continence by conservative management. Of the 22 group B patients, 11 reported socially acceptable continence by conservative management. Vesical compliance was significantly higher in cases who reported socially acceptable continence than in those with incontinence persistent regarding all participants (10 +/- 7.2 vs 6.8 +/- 6.2 mL/cmH(2)O, P = 0.0347) and group A (9.1 +/- 6.7 vs 3.7 +/- 1.4 mL/cmH(2)O, P = 0.0350). Leak point pressure was significantly higher in patients who obtained socially acceptable continence than in those having persistent incontinence regarding all participants (50 +/- 17.2 vs 25 +/- 6.6 mL/cmH(2)O, P = 0.0003), group A (51 +/- 21.4 vs 26 +/- 7.2 mL/cmH(2)O, P = 0.0348) and also, group B (49 +/- 12.8 vs 23.7 +/- 6.3 mL/cmH(2)O, P = 0.0043).
    Conclusion: In our series, socially acceptable continence was obtained in only 20 patients (52%) by conservative management. The present study suggests that the limitation of conservative treatment seems to be apparent when they have urethral closure deficiency and/or intractable poor vesical compliance.

    DOI: 10.1111/j.1757-5672.2010.00070.x

    Web of Science

    PubMed

    researchmap

  • Kinetics of serum total and free prostate-specific antigen (PSA) after extended multisite prostate biopsy: Comparison among biopsy, transurethral resection of the prostate (TURP), and biopsy plus TURP 査読

    Noboru Hara, Hiroshi Koike, Tomohiro Nobushita, Norio Miyajima, Makoto Kawaguchi, Tsutomu Nishiyama, Kota Takahashi, Rudolf Hohenfellner

    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS   28 ( 4 )   355 - 359   2010年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE INC  

    Background: The kinetics and reproducibility of serum prostate-specific antigen (PSA) following extended multisite biopsies are unknown. The aim of this study was to examine the kinetics of hematogenous leakage of PSA molecules by comparing the postintervention PSA manner among extended biopsies, transurethral resection of the prostate (TURP) and biopsy plus TURP.
    Methods: Total and free PSA values were examined before and sequentially after intervention (at 1 hour, 24 hours, 2 days, 14 days, and 28 days), in patients who underwent 14-core prostate biopsy (Biopsy, n = 53), TURP (TURP, n = 21), or prostate biopsy plus TURP (Biopsy+TURP, n = 18).
    Results: Ten patients in the Biopsy group were histologically diagnosed as having prostate cancer, and all other patients were diagnosed with non-malignant disorders. One hour after intervention, the increase in total PSA in the Biopsy group (mean 19.58 +/- 24.78-fold) and Biopsy+TURP group (mean 14.00 +/- 10.52-fold) was higher than that of the TURP group (mean 6.189 +/- 7.567-fold) (P = 0.0207 and 0.0119, respectively). The increase in total PSA in the Biopsy+TURP group was not different from that of the Biopsy group. The increase in free PSA in the Biopsy group (mean 36.52 +/- 21.18-fold or more) was greater than that of the TURP group (mean 15.57 +/- 18.17-fold) (P = 0.0002 or less). Both total and free PSA values in the Biopsy group recovered to the initial levels 28 days after intervention (P = 0.380 and P = 0.0873, respectively). The course of both total and free PSA values in the Biopsy group was not different between prostate cancer and non-malignant disorders.
    Conclusions: Extended multisite biopsies caused marked elevation of both total and free PSA compared with ordinary sextant protocol or TURP, and they reduced to the preoperative levels in about 4 weeks. The postintervention increase of PSA and its manner of recovery were comparable between the Biopsy and Biopsy+TURP groups, suggesting that the hematogenous leakage of PSA by biopsies occurs in an early phase just after biopsy and rapidly reduces also in the early phase. (c) 2010 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.urolonc.2008.10.014

    Web of Science

    PubMed

    researchmap

  • Parathyroid hormone-related peptide-producing non-familial pheochromocytoma in a child 査読

    Keisuke Takeda, Noboru Hara, Makoto Kawaguchi, Tsutomu Nishiyama, Kota Takahashi

    INTERNATIONAL JOURNAL OF UROLOGY   17 ( 7 )   673 - 676   2010年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    We experienced a case of parathyroid hormone-related peptide (PTHrP)-producing pheochromocytoma, which was found in a 12-year-old boy with hypercalcemia. The leading symptom was abdominal pain, and severe hypertension and tachycardia were noticed at the initial visit. His medical and familial histories were unremarkable. Laboratory examinations showed hypercalcemia (3.3 mmol/L of serum-calcium). Computed tomography showed a heterogeneous mass measuring 5.0 cm in the right adrenal gland, which had abnormal uptake with 123-I metaiodobenzylguanidine scintigraphy. Serum/urine catecholamines were highly elevated, and serum PTHrP also increased (1.4 pmol/L). The patient underwent laparoscopic right adrenalectomy. The tumor was histologically diagnosed as typical pheochromocytoma and the expression of PTHrP was confirmed with immunohistochemistry. The serum PTHrP level was normalized after surgery. He was free of disease postoperatively for 12 months. There has been no described pediatric patient with PTHrP-producing pheochromocytoma. We showed evidence that the present tumor is a complex neoplasm involving various neuroendocrine activities with the dual-lineage differentiation.

    DOI: 10.1111/j.1442-2042.2010.02555.x

    Web of Science

    PubMed

    researchmap

  • Decline of the Red Blood Cell Count in Patients Receiving Androgen Deprivation Therapy for Localized Prostate Cancer: Impact of ADT on Insulin-like Growth Factor-1 and Erythropoiesis 査読

    Noboru Hara, Tsutomu Nishiyama, Itsuhiro Takizawa, Toshihiro Saito, Yasuo Kitamura, Kota Takahashi

    UROLOGY   75 ( 6 )   1441 - 1445   2010年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE INC  

    OBJECTIVES To elucidate the mechanism of blood hemoglobin loss in patients with prostate cancer during androgen deprivation therapy (ADT), and to examine the activity of the growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis during ADT, which plays an important role in hematopoiesis.
    METHODS A total of 83 patients with localized prostate cancer, who received ADT, were prospectively studied on the basis of their blood samples at the baseline and after ADT for 6 months.
    RESULTS Before ADT, the IGF-1 level was correlated with the red blood cell (RBC) count (Spearman's rank correlation coefficient analysis [rs] = 0.315, P = .011), hemoglobin (rs = 0.278, P = .018), and mean corpuscular volume (rs = 0.266, P = .020), but such relationships disappeared after ADT. After ADT, the serum IGF-1 level increased compared with that at the baseline (21 +/- 6 vs 18 +/- 5 nmol/L, respectively, P <.001), but no change was observed in the serum GH level (P = .691). There was no difference between erythropoietin and interleukin-6 concentrations before and after ADT (P = .852 and P = .208, respectively). The hemoglobin concentration and RBC count declined after ADT compared with those before treatment (P <.001 for each). Although the mean corpuscular volume declined after ADT (P = .002), the mean cell hemoglobin was comparable between before and after ADT (P = .676).
    CONCLUSIONS Despite the unaffected GH, erythropoietin, and interleukin-6 levels, the serum IGF-1 concentration was elevated by ADT. Even with the increased IGF-1 level, the RBC count and hemoglobin concentration declined after ADT. IGF-1 in the bone marrow erythroid progenitor cells might be functionally inactivated during ADT. UROLOGY 75: 1441-1445, 2010. (c) 2010 Elsevier Inc.

    DOI: 10.1016/j.urology.2009.11.021

    Web of Science

    PubMed

    researchmap

  • Successful treatment of nonocclusive mesenteric ischemia that developed during the peritransplant period following ABO-incompatible kidney transplantation 査読

    Masayuki Tasaki, Kazuhide Saito, Yuki Nakagawa, Noboru Hara, Akifumi Kuwabara, Shintaro Komukai, Manabu Ohashi, Haruhiko Okamoto, Toshiki Tanikawa, Tsutomu Nishiyama, Kota Takahashi

    CLINICAL AND EXPERIMENTAL NEPHROLOGY   14 ( 2 )   199 - 202   2010年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    Nonocclusive mesenteric ischemia (NOMI) is an infrequent and fatal disorder. We describe a 54-year-old man who developed NOMI during the peritransplant period following ABO-incompatible living-donor kidney transplantation, but who was successfully treated with his renal graft function unimpaired. Abdominal pain appeared on the sixth postoperative day (POD), and emergency surgery was performed on POD 8. Discontinuous segmental necrosis extended throughout the small intestine, and the necrotic segments were entirely removed. He thereafter had ischemia of the ascending colon, which was treated with colectomy, and prostaglandin E1 delivered through the related artery prevented advanced necrosis. Temporary colostomy was closed 20 months after surgery. He maintains excellent graft function at present without secondary disorder. There has been no ABO-incompatible kidney transplant recipient complicated with NOMI. However, patients with end-stage renal disease are at the highest risk for this lethal condition, and physicians and urologists should correctly recognize its diagnostics and therapeutics.

    DOI: 10.1007/s10157-009-0232-0

    Web of Science

    PubMed

    researchmap

  • Mechanism of Acute Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation: Which Anti-A/Anti-B Antibodies are Responsible, Natural or de Novo? 査読

    Kota Takahashi, Kazuhide Saito, Yuki Nakagawa, Masayuki Tasaki, Noboru Hara, Naofumi Imai

    TRANSPLANTATION   89 ( 5 )   635 - 637   2010年3月

     詳細を見る

    記述言語:英語   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    DOI: 10.1097/TP.0b013e3181c89307

    Web of Science

    PubMed

    researchmap

  • Bone Metabolic Disorder in Patients With Prostate Cancer Receiving Androgen Deprivation Therapy (ADT): Impact of ADT on the Growth Hormone/Insulin-Like Growth Factor-1/Parathyroid Hormone Axis 査読

    Etsuko Isahaya, Noboru Hara, Tsutomu Nishiyama, Tatsuhiko Hoshii, Itsuhiro Takizawa, Kota Takahashi

    PROSTATE   70 ( 2 )   155 - 161   2010年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-LISS  

    BACKGROUND. Although androgen deprivation therapy (ADT) has been associated with bone loss in patients with prostate cancer, its mechanism remains unclear. The growth hormone (GH)/insulin-like growth factor-1 (IGF)-1/parathyroid hormone (PTH) axis plays a critical role in bone synthesis, but its activity during ADT is also unknown.
    METHODS. Seventy-one patients with localized prostate cancer, who received ADT, were prospectively studied based on their bone mineral density (BMD) and blood and urine samples at the baseline and after ADT for 6 months.
    RESULTS. The IGF-1 level was correlated with BMD before ADT (rs = 0.325, P = 0.007), but such a relationship disappeared after ADT (P = 0.565). Following ADT, the serum IGF-1 level increased compared with that at the baseline (22 +/- 6 nmol/L vs. 19 +/- 5 nmol/L, respectively, P < 0.001). The serum PTH level was reduced after ADT (41 +/- 33 ng/L) compared with the baseline (55 +/- 44 ng/L) (P < 0.001), but no change was observed in the serum GH level (P = 0.691). Bone resorption markers such as blood N-telopeptide (NTx), urinary NTx, calcium, and inorganic phosphorus levels increased after ADT (P < 0.001 in all). The ratio of the IGF-1 level after ADT/before ADT was associated with the ratio of the value after ADT/before ADT of alkaline phosphatase (rs = 0.266, P = 0.025) and calcium (rs = 0.242, P = 0.042).
    CONCLUSION. Despite the unaffected GH and upregulated bone resorption, the serum IGF-1 level was elevated by ADT. The IGF-1 level was correlated with BMD before ADT, but the relationship was disrupted after ADT. IGF-1 or its receptor in the bone may be functionally inactivated during ADT. Prostate 70: 155-161, 2070. (C) 2009 Wiley-Liss, Inc.

    DOI: 10.1002/pros.21047

    Web of Science

    PubMed

    researchmap

  • Oncological results, functional outcomes and health-related quality-of-life in men who received a radical prostatectomy or external beam radiation therapy for localized prostate cancer: a study on long-term patient outcome with risk stratification 査読

    Itsuhiro Takizawa, Noboru Hara, Tsutomu Nishiyama, Masaaki Kaneko, Tatsuhiko Hoshii, Emiko Tsuchida, Kota Takahashi

    ASIAN JOURNAL OF ANDROLOGY   11 ( 3 )   283 - 290   2009年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    Health-related quality-of-life (HRQOL) after a radical prostatectomy (RP) or external beam radiation therapy (EBRT) has not been studied in conjunction with oncological outcomes in relation to disease risk stratification. Moreover, the long-term outcomes of these treatment approaches have not been studied. We retrospectively analyzed oncological outcomes between consecutive patients receiving RP (n = 86) and EBRT (n = 76) for localized prostate cancer. HRQOL and functional outcomes could be assessed in 62 RP (79%) and 54 EBRT (79%) patients over a 3-year follow-up period (median: 41 months) using the Medical Outcomes Study Short Form-36 (SF-36) and the University of California Los Angeles Prostate Cancer Index (UCLA PCI). The 5-year biochemical progression-free survival did not differ between the RP and EBRT groups for low-risk (74.6% vs. 75.0%, P = 0.931) and intermediate-risk (61.3% vs. 71.1%, P = 0.691) patients. For high-risk patients, progression-free survival was lower in the RP group (45.1%) than in the EBRT group (79.7%) (P = 0.002). The general HRQOL was comparable between the two groups. Regarding functional outcomes, the RP group reported lower scores on urinary function and less urinary bother and sexual bother than the EBRT group (P < 0.001, P < 0.05 and P < 0.001, respectively). With risk stratification, the low-and intermediate-risk patients in the RP group reported poorer urinary function than patients in the EBRT group (P < 0.001 for each). The sexual function of the high-risk patients in the EBRT group was better than that of the same risk RP patients (P < 0.001). Biochemical recurrence was not associated with the UCLA PCI score in either group. In conclusion, low-to intermediate-risk patients treated with an RP may report relatively decreased urinary function during long-term follow-up. The patient's HRQOL after treatment did not depend on biochemical recurrence.

    DOI: 10.1038/aja.2009.10

    Web of Science

    PubMed

    researchmap

  • Management for patients with de novo or recurrent tumors in the residual kidney after surgery for nonfamilial bilateral renal cell carcinoma 査読

    Noboru Hara, Tsutomu Nishiyama, Norihiko Yoshimura, Satoshi Takaki, Kyoichiro Yamakado, Yasuo Kitamura, Kazuya Suzuki, Kota Takahashi

    Advances in Urology   135143   2009年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The tumor de novo in the residual kidney after surgery for nonfamilial bilateral renal cell carcinoma (RCC) is problematic. We reviewed 5 patients who experienced such a situation. Three patients had had metachronous bilateral RCC, treated with radical nephrectomy in one kidney and nephron-sparing surgery (NSS) in the other. Two patients had had synchronous disease
    one patient had received radical nephrectomy and NSS, and the other bilateral NSS. The 5 patients had another solid mass/de novo tumor in the residual kidney 16-88 (mean 46.8) months after surgery. For the tumor de novo in earlier years (1992-1999), one patient underwent surgery and hemodialysis, and the other selected a conservative observation. In recent years (2000-2007), one patient was conservatively observed
    the remaining 2 received computerized-tomography-guided radiofrequency ablation, and the local tumors were well controlled postoperatively for 20 and 12 months with their renal function unimpaired. Ablative techniques can potentially strike a balance between oncological and nephrological outcomes in patients with sporadic multiple RCC, successful management of which was difficult previously. © 2009 Noboru Hara et al.

    DOI: 10.1155/2009/135143

    Scopus

    PubMed

    researchmap

  • Editorial Comment on: Role of Dynamic Contrast-Enhanced Magnetic Resonance (MR) Imaging and Proton MR Spectroscopic Imaging in the Detection of Local Recurrence after Radical Prostatectomy for Prostate Cancer 査読

    Noboru Hara

    European Urology   54 ( 3 )   598 - 599   2008年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.eururo.2007.12.035

    Scopus

    PubMed

    researchmap

  • Perioperative antibiotics in radical cystectomy with ileal conduit urinary diversion: Efficacy and risk of antimicrobial prophylaxis on the operation day alone 査読

    Noboru Hara, Yasuo Kitamura, Toshihiro Saito, Shuichi Komatsubara, Tsutomu Nishiyama, Kota Takahashi

    INTERNATIONAL JOURNAL OF UROLOGY   15 ( 6 )   511 - 515   2008年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    Objective: To determine the optimum schedule for perioperative antimicrobial prophylaxis (AMP) for bladder cancer patients submitted to radical cystectomy with ileal conduit urinary diversion.
    Methods: We studied 77 consecutive bladder cancer patients who underwent radical cystectomy with ileal conduit. The 1-day group (n = 33) received pre-, intra- and postoperative administrations of 2 g of piperacillin on the operation day alone; the 3-day group (n = 44) received antibiotics for 3 days or more (same schedule as the 1-day group on the operation day and every 12 h thereafter). The study was designed and postoperative complications including surgical-site infection (SSI) were defined according to the modified Centers for Disease Control and Prevention criteria.
    Results: No significant differences were found between the 1-day group and 3-day group in terms of total SSI (18.1% vs 20.5%), superficial incisional SSI (12.1% vs 13.6%), deep incisional SSI (12.1% vs 13.6%), space SSI (12.1% vs 11.4%), postoperative ileus (18.2% vs 11.4%), febrile urinary tract infections (15.2% vs 15.9%) or pneumonia (3.0% vs 4.3%), respectively. In both groups, disease stage and patients' underlying conditions such as diabetes did not have an influence on the incidence of postoperative complications.
    Conclusion: One-day AMP had equivalent efficacy to that of the standard prophylaxis protocol for preventing septic complications following radical cystectomy with ileal conduit. This finding supports the hypothesis that delivery of antibiotics on the operation day is critical in this setting.

    DOI: 10.1111/j.1442-2042.2008.02050.x

    Web of Science

    PubMed

    researchmap

  • Primary solitary fibrous tumor (SFT) in the retroperitoneum 査読

    Itsuhiro Takizawa, Toshihiro Saito, Yasuo Kitamura, Kei Arai, Makoto Kawaguchi, Kota Takahashi, Noboru Hara

    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS   26 ( 3 )   254 - 259   2008年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE INC  

    Background: Solitary fibrous tumor (SFT) is an infrequent but distinct neoplasm, which generally arises from submesothelial connective tissue in the pleura. SFT is rarely recognized in extrathoracic sites, and histologically identical conditions have also been reported in the retroperitoneum, although their pathophysiology has not been extensively investigated.
    Methods: We present four cases of primary SFT in the retroperitoneum, and review 37 similar cases in the previous literature.
    Results: About 40% of patients were asymptomatic, and 19.2% and 15.4% presented with an abdominal mass and urinary symptoms, respectively. The tumor size ranged between 2 and 26 (mean 9.1) cm. Sixty-three percent of tumors showed nonspecific development with haphazard distribution of bland short spindle or polygonal cells with or without collagenous bundles and stromal hyalinization. In 22.0%, hemangiopericytomatous appearance was seen. About 15% of cases showed histologically malignant characteristics. The tumor cells were immunoreactive for vimentin in all cases, CD34 in 91% and Bcl-2 in 86%. All tumors were excised, and in 85.4% of cases, tumors did not recur postoperatively for 6 to 48 months. No significant difference was found between the recurrence rate of histologically benign and malignant cases. Cases positive for both CD34 and Bcl-2 had no recurrence.
    Conclusions: The identification of SFT in the retroporitoneum is of importance because histopathological indicators of malignancy are not necessarily associated with clinical malignant potential in many cases of retroperitoneal SFT. Retroperitoneal SFT showing typical pathological features with expression of CD34 and Bcl-2 is associated with a favorable outcome following excision. (C) 2008 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.urolonc.2007.03.024

    Web of Science

    PubMed

    researchmap

  • Renal cell carcinomas arising from the allograft and bilateral native kidneys 査読

    Tomohiro Nobushita, Noboru Hara, Yuki Nakagawa, Kazuhide Saito, Tsutomu Nishiyama, Kota Takahashi

    INTERNATIONAL JOURNAL OF UROLOGY   15 ( 2 )   175 - 177   2008年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BLACKWELL PUBLISHING  

    We present the case of a young lady who developed renal cell carcinomas (RCC) in the allograft and bilateral native kidneys metachronously within one year. She received a living donor kidney transplantation from her father. A solid tumor of 4 cm in diameter was uncovered first in the allograft kidney 103 months after transplantation, and was treated with graftectomy. Six months after graftectomy, a right renal tumor measuring 3.5 cm and left renal tumors emerged in the native kidneys. She underwent laparoscopic right and left radical nephrectomy in separate sessions. The pathological diagnosis in the allograft and right renal tumors was clear cell RCC with eosinophilic cytoplasm and that in the left kidney was clear cell carcinoma. Fluorescence in situ hybridization and human leukocyte antigen typing showed that each tumor was most probably primary disease. She was free of disease 18 months postoperatively. This is the first report on RCC arising both in the allograft and bilateral native kidneys.

    DOI: 10.1111/j.1442-2042.2007.01941.x

    Web of Science

    PubMed

    researchmap

  • High incidence of GalNAc disialosyl lactotetraosylceramide in metastatic renal cell carcinoma 査読

    Ryo Maruyama, Seiichi Saito, Vladimir Bilim, Noboru Hara, Toshiyuki Itoi, Kazutoshi Yamana, Tsutomu Nishiyama, Yoichi Arai, Kota Takahashi, Yoshihiko Tomita

    ANTICANCER RESEARCH   27 ( 6C )   4345 - 4350   2007年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:INT INST ANTICANCER RESEARCH  

    Background: In renal cell carcinoma (RCC), glycosphingolipids monosialosyl globopentaosylceramide (MSGb5) and GalNAc disialosyl lactotetraosylceramide (GalNAcDSLc4) were shown to be predictors of metastasis. Here we extended the research using a larger cohort of patients with a longer follow-up period, and reevaluate their relationship to malignant potential, metastasis and prognosis in patients with RCC. Patients and Methods: MSGb5 and GalNAcDSLc4 were examined in 114 primary RCCs by immunohistochemical method on ctyostat sections. Results: GalNAcDSLc4 was detected in 13.2% of RCCs and was associated with a significantly higher incidence of metastasis at the time of primary visit (60.0% vs. 31.3%, p=0.0419) as well as de novo metastasis during follow-up (33.3% vs. 14.7%), and a shorter survival (p=0.0399). MSGb5 was detected in 51.8% of tumors and was not related to clinocopathological characteristics or survival. Conclusion: RCC patients with tumors positive for GalNAcDSLc4 are at higher risk of metastasis at the time of diagnosis and during follow-up.

    Web of Science

    PubMed

    researchmap

  • Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer 査読

    Toshihiro Saito, Noboru Hara, Yasuo Kitamura, Shuichi Komatsubara

    UROLOGY   70 ( 4 )   702 - 705   2007年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE INC  

    OBJECTIVES Novel prognostic indexes clinically applicable for patients with Stage IV prostate cancer are needed because prostate-specific antigen (PSA) tests occasionally fail to reflect the prognostic outcome. We investigated various clinicopathologic parameters in men with Stage IV prostate cancer and evaluated the utility of the PSA/prostatic acid phosphatase (PAP) ratio as a prognostic index.
    METHODS We reviewed 241 patients with Stage IV prostate cancer, who were treated in Niigata Cancer Center Hospital from 1992 to 2004. Survival Curves were generated using the Kaplan-Meier method. Univariate and multivariate analyses of survival associations, including age, performance status, clinical presentation, disease localization, pathologic findings, and serologic markers, were conducted using the log-rank test and Cox proportional hazard models.
    RESULTS The 5-year overall survival rate using the Kaplan-Meier method for all 241 patients was 43.0%. No significant difference was found in the Survival rates according to PSA level. However, the 5-year survival rate was significantly lower in patients with a PSA/PAP ratio of less than 3.0 (P = 0.0022): 24.2% and 48.0% in those with a PSA/PAP ratio of less than 3.0 and 3.0 or greater, respectively. On multivariate analysis using the proportional hazards model, the statistically significant prognostic factors of overall survival were alkaline phosphatase (P = 0.0413), lactate dehydrogenase (P = 0.0409), and the PSA/PAP ratio (P = 0.0113).
    CONCLUSIONS The PSA/PAP ratio is a valuable prognostic indicator in men with Stage IV prostate cancer. Although our study found that other laboratory tests also had a prognostic influence, the PSA/PAP ratio was an essential index implicated in the physiopathology of prostate cancer.

    DOI: 10.1016/j.urology.2007.05.019

    Web of Science

    PubMed

    researchmap

  • Evaluation of magnetic resonance imaging-based prostate-specific antigen density of the prostate in the diagnosis of prostate cancer 査読

    Tatsuhiko Hoshii, Tsutomu Nishiyama, Shinichi Toyabe, Kohei Akazawa, Shuichi Komatsu, Masaaki Kaneko, Noboru Hara, Kota Takahashi

    INTERNATIONAL JOURNAL OF UROLOGY   14 ( 4 )   305 - 310   2007年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BLACKWELL PUBLISHING  

    Objectives: We evaluated prostate-specific antigen (PSA) density of the prostatic volume (PSAD) estimated using transrectal ultrasonography (TRUS; TRUS-based PSAD), magnetic resonance imaging (MRI; MRI-based PSAD), and PSA density of the transition zone (TZ) volume (PSATZD) estimated using MRI (MRI-based PSATZD) in the diagnosis of prostate cancer (PCa).
    Methods: One hundred and twenty patients, who were suspected to have PCa based on PSA, ranged between 4.1 and 20.0 ng/mL were enrolled in this study.
    Results: The prostatic volume estimated using TRUS was smaller than the volume estimated using MRI by 11.4% in the patients with PSA levels ranging 4.1-20.0 ng/mL, 7.2% in those 4.1-10.0 ng/mL, and 15.7% in those 10.1-20.0 ng/mL, respectively. PSA levels were correlated with the prostatic volume estimated using TRUS and MRI, and TZ volume estimated using MRI in the patients without PCa; however, the level was not correlated with them in the patients with PCa. The area under the receiver operating characteristic curve of MRI-based PSAD was higher than that of TRUS-based PSAD; however, there was no statistical difference. Stepwise logistic regression analysis for the prediction of PCa by using PSA-related parameters confirmed that MRI-based PSATZD was the most significant predictor in patients with PSA levels in the range of 4.1-20.0 ng/mL (P < 0.001), the range of 4.1-10.0 ng/mL (P=0.002), and the range of 10.1-20.0 ng/mL (P < 0.001), respectively.
    Conclusions: The prostatic volume estimated using TRUS was smaller than the volume estimated using MRI. MRI-based PSATZD is the most significant predictor in the four parameters.

    DOI: 10.1111/j.1442-2042.2007.01686.x

    Web of Science

    PubMed

    researchmap

  • Idiopathic retroperitoneal fibrosis associated with IgG4-positive-plasmacyte infiltrations and idiopathic chronic pancreatitis 査読

    Norio Miyajima, Hiroshi Koike, Makoto Kawaguchi, Yo Zen, Kota Takahashi, Noboru Hara

    INTERNATIONAL JOURNAL OF UROLOGY   13 ( 11 )   1442 - 1444   2006年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BLACKWELL PUBLISHING  

    Idiopathic retroperitoneal fibrosis (IRPF) is an inflammatory fibrosclerosing condition, leading to renal failure by obstruction of the ureters. Idiopathic chronic pancreatitis associated with marked inflammatory infiltrates has recently been referred to as autoimmune pancreatitis (AIP), and infiltrating plasmacytes carrying immunoglobulin-gamma type 4 (IgG4) are relevant to its pathogenesis. The case is described herein of IRPF associated with subclinical pancreatitis that was most probably AIP in a 70-year-old man. Biopsy specimens of the retroperitoneal pseudotumor revealed a marked lymphoplasmacytic infiltration with dense fibrosis. Infiltrating plasma cells were immunoreactive for anti-IgG4 antibodies. Subsequent systemic examinations showed an extremely elevated serum IgG4 level and pancreatitis concordant with AIP. Following oral steroid administration, the serum IgG4 level normalized, although the appearance of the pseudotumor did not alter. Some AIP cases have been associated with idiopathic fibrosclerosing disorders including IRPF, but histological evidence of IgG4-related IRPF has rarely been provided.

    DOI: 10.1111/j.1442-2042.2006.01568.x

    Web of Science

    PubMed

    researchmap

  • Homozygous deletions of the INK4a/ARF locus in renal cell cancer 査読

    Takashi Kasahara, Vladimir Bilim, Noboru Hara, Kota Takahashi, Yoshihiko Tomita

    ANTICANCER RESEARCH   26 ( 6B )   4299 - 4305   2006年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:INT INST ANTICANCER RESEARCH  

    Background: Genetic alterations of p14(ARF) contribute to dysfunction of p53 pathways by disruption of MDM2-mediated inhibition of p53. P14(ARF) was investigated by focusing on the homozygous deletion (HD) in the INK4a/ARF locus and hypermethylation of the p14ARF promoter in renal cell cancer (RCC). Materials and Methods: Using 6 RCC cell lines, RT-PCR and Western blotting was performed for p14(ARF) DNA from 34 RCCs was analyzed for HD in the INK4a/ARF locus, promoter hypermethylation and p53 gene mutation. Results: HD was confirmed in 4 out of 6 cell lines and in 8 out of 34 (23.5%) RCC specimens, which correlated with the presence of metastasis, high tumor grade and had a tendency to more advanced stage (I vs. II-IV). No hypermethylation of the p14(ARF) promoter or p53 mutation was detected among the RCC specimens. Conclusion: These results indicate that the deletion in the INK4a/ARF locus might contribute to tumor progression in RCC at least partly by functional inactivation of wild-type p53.

    Web of Science

    PubMed

    researchmap

  • Outcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan 査読

    Toshihiro Saito, Yasuo Kitamura, Shuichi Komatsubara, Yasuo Matsumoto, Tadashi Sugita, Noboru Hara

    ASIAN JOURNAL OF ANDROLOGY   8 ( 5 )   555 - 561   2006年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BLACKWELL PUBLISHING  

    Aim: To investigate the outcomes for Asian populations with locally advanced/clinical stage III prostate cancer (PCa) treated with currently prevailing modalities. Methods: We reviewed the record of 209 patients with clinical stage III PCa, who were treated at Niigata Cancer Center Hospital between 1992 and 2003. Treatment options included hormone therapy-combined radical prostatectomy (RP+HT), hormone therapy-combined external beam irradiation (EBRT+HT) and primary hormone therapy (PHT). Results: The 5- and 10-year overall survival rates were 80.3% and 46.1% in all cohorts, respectively. The survival rates were 87.3% and 66.5% in the RP+HT group, 94.9% and 70.0% in the EBRT+HT group and 66.1% and 17.2% in the PHT group, respectively. A significant survival advantage was found in the EBRT+HT group compared with that in the PHT group (P < 0.0001). Also, the RP+HT group had better survival than the PHT group (P= 0.0107). The 5- and 10-year disease-specific survival rates for all cases were 92.5% and 80.0%, respectively. They were 93.8% and 71.4% in the RP+HT group, 96.6% and 93.6% in the EBRT+HT group and 88.6% and 62.3% in the PHT group, respectively. A survival advantage was found in the EBRT+HT group compared with the PHT group (P= 0.029). No significant difference was found in disease-specific survival between the EBRT+HT and RP+HT groups or between the RP+HT and PHT groups. Conclusion: Although our findings indicate that radiotherapy plus HT has a survival advantage in this stage of PCa, we recommend therapies that take into account the patients' social and medical conditions for Asian men with clinical stage III PCa.

    DOI: 10.1111/j.1745-7262.2006.00175.x

    Web of Science

    PubMed

    researchmap

  • Primary gastrointestinal stromal tumor in the retroperitoneum 査読

    Itsuhiro Takizawa, Hideo Morishita, Shingo Matsuki, Takeshi Komeyama, Iwao Emura, Noboru Hara

    INTERNATIONAL JOURNAL OF UROLOGY   13 ( 9 )   1245 - 1248   2006年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BLACKWELL PUBLISHING  

    Gastrointestinal stromal tumor (GIST) is the most frequent non-epithelial neoplasm in the gastrointestinal tract. GIST has received much attention both for its clinical significance and biological nature, while the retroperitoneal condition identical to GIST has been rarely described. Presented herein is a case of GIST arising from the retroperitoneum in a 67-year-old man. The solid tumor measuring 4 cm was uncovered in the retroperitoneum, between the abdominal aorta and inferior vena cava, on computed tomography. The patient underwent surgical excision of the tumor. Histological examination showed proliferating spindle cells in the clearly demarcated tumor; immunoreactivity for Kit and CD34 in tumor cells confirmed the diagnosis of GIST. The histological origin of GIST is suggested to be gastrointestinal pacemaker cells, because they share specific immunoreactivity for CD117/Kit, which is also relevant to pathogenesis of GIST. The present case was a rare primary GIST in the retroperitoneum with typical immunopathological features.

    DOI: 10.1111/j.1442-2042.2006.01545.x

    Web of Science

    PubMed

    researchmap

  • Total and free prostate-specific antigen indexes in prostate cancer screening: value and limitation for Japanese populations 査読

    N Hara, Y Kitamura, T Saito, S Komatsubara

    ASIAN JOURNAL OF ANDROLOGY   8 ( 4 )   429 - 434   2006年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BLACKWELL PUBLISHING  

    Aim: To assess the efficacy and limitation of free/total prostate-specific antigen ratio (f/tPSA) at a single institution in Japan, focusing on the avoidance of pointless prostate biopsies. Methods: In total, 631 men between 44 and 93 years old (mean 69.8 years) with elevated PSA underwent power-Doppler ultrasoundgraphy-guided transrectal 10-core prostate biopsies at Niigata Cancer Center Hospital, and their histological features were investigated with total PSA (tPSA) and f/tPSA. Results: PCa was detected in 126 of 134 patients (94.3%) with tPSA of 26 ng/mL or higher. The detection rate was 59.4% for tPSA of 21-25 ng/mL, followed by 39.2% for 16-20 ng/mL, 30.0% for 11-15 ng/mL, 20.0% for 4.1-10 ng/mL and 7.6% for <= 4.0 ng/mL. f/tPSA of the PCa group was significantly lower than that of non-malignamt disorders in any tPSA ranges (mean 0.122 vs. 0.160, P < 0.001). Receiver-operating characteristics analyses showed that f/tPSA (AUC: 0.664) performed more valuably than tPSA (AUC: 0.559) in patients with tPSA between 3.0-10 ng/mL (P < 0.01). Although f/tPSA of 0.250 for the cut-off value might miss 1.8% PCa patients, it potentially spares 9.2% of unnecessary biopsies. Conclusion: f/tPSA is more valuable compared with tPSA alone for the prediction of the occurrence of PCa. We recommend 0.250 as the cut-off value for f/tPSA in PCa screening for Asian men having so-called grey-zone tPSA.

    DOI: 10.1111/j.1745-7262.2006.00155.x

    Web of Science

    PubMed

    researchmap

  • Efficacy of extracorporeal shockwave lithotripsy with patients rotated supine or rotated prone for treating ureteral stones: A case-control study 査読

    N Hara, H Koike, Bilim, V, K Takahashi, T Nishiyama

    JOURNAL OF ENDOUROLOGY   20 ( 3 )   170 - 174   2006年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:MARY ANN LIEBERT INC  

    Purpose: To improve the therapeutic efficacy of extracorporeal shockwave lithotripsy (SWL) for ureteral stones by attempting semilateral/rotated approaches. There has been no study that shows the advantage of rotated positions.
    Patients and Methods: Two hundred forty-eight (group 1) and 156 (group 1R) patients with proximal-ureteral stones were treated by the Dornier Lithotriptor U15/50 in the supine and rotated-supine position, respectively. When residual calculi remained in the middle-distal ureter, group 1 subjects underwent subsequent sessions in the ordinary prone position, and Group 1R patients were treated in the rotated-prone position. Sixty-two (group 2) and 60 (group 2R) patients with primary middle-ureteral stones were treated in the prone and rotated-prone position, respectively, while 110 (group 3) and 98 (group 3R) patients with distal-ureteral stones were treated in the prone and rotated-prone position, respectively.
    Results: Although the stone-free rate was not different in group 1 (94.8%) and 1R (97.4%), the number of sessions required for Group 1R patients to be stonefree (mean 1.49) was less than for Group 1 patients (mean 1.74; p = 0.023). Group 1R patients tolerated a higher shockwave intensity than group 1 patients for sessions in the proximal ureter (p = 0.042). The stone-free rate for Groups 1 and 1R for booster sessions in the middle-distal ureter was 85.4% and 100%, respectively (p = 0.059). The stone-free rate for groups 211 (95.0%) and 3R (98.0%) was higher than that for groups 2 (83.9%) and 3 (89.1%) (p = 0.046; p = 0.011).
    Conclusion: These effortless modifications bring about a superior outcome when treating ureteral calculi with SWL.

    DOI: 10.1089/end.2006.20.170

    Web of Science

    PubMed

    researchmap

  • Obstruction of the ileal ureter by mesenteric vessels occurring 5 years after total ureteral substitution for bilateral ureteral stenosis due to systemic lupus erythematosus 査読

    K Kobayashi, K Obara, R Watanabe, N Hara, A Katagiri, K Takahashi

    INTERNATIONAL JOURNAL OF UROLOGY   13 ( 1 )   80 - 83   2006年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BLACKWELL PUBLISHING  

    We previously reported a case of bilateral ureteral stenosis accompanied by systemic lupus erythematosus, which was successfully managed by total ureteral reconstruction using a segment of the ileum. Herein, we describe an unusual complication in the same patient, which we experienced 5 years after the ileal-ureteral substitution. Left-sided back pain repeated together with transient obstruction of the ileal ureter interposed between the right and left renal pelvis. Consequently, exploratory laparotomy revealed that left colic vessels oppressed and caused obstruction, and the obstructed ileal ureter was released by reconstitution of these vessels instead of re-anastomosis of the ileal ureter. Left hydronephrosis and related back pain disappeared postoperatively. The number of patients with an indication of ileal-ureteral substitution is increasing for various disorders, and thus, the present report gives additional suggestions for the follow up of patients with ileal ureter.

    DOI: 10.1111/j.1442-2042.2006.01232.x

    Web of Science

    PubMed

    researchmap

  • Transforming growth factor-beta 1 regulates cell growth and causes downregulation of SMemb/non-muscle myosin heavy chain B mRNA in human prostate stromal cells 査読

    K Obara, Bilim, V, K Suzuki, K Kobayashi, N Hara, T Kasahara, T Nishiyama, K Takahashi

    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY   39 ( 5 )   366 - 371   2005年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:TAYLOR & FRANCIS AS  

    Objectives. SMemb/non-muscle myosin heavy chain B (SMemb/NMMHC-B) is most abundantly expressed in proliferating smooth muscle cells and correlates with phenotypic changes from a contractive to a proliferative type. The stromal cells of the prostate play a crucial role in the regulation of prostatic growth and function. The aim of this study was to investigate the effects of the multifunctional cytokine transforming growth factor-beta 1 (TGF-beta 1) on SMemb/NMMHC-B mRNA expression and stromal cell growth. The expression of the SM2 isoform of smooth muscle myosin heavy chain (SMMHC) mRNA was also examined. Material and methods. Primary cultures of prostate stromal cells were established by means of an explant method from eight normal prostates. The effects of TGF-beta 1 on stromal cell growth were determined by means of a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide conversion assay. SMemb/NMMHC-B and SM2 mRNA expression were analyzed quantitatively by means of real-time polymerase chain reaction. Results. In the absence of TGF-beta 1, cells expressed alpha-smooth muscle actin and vimentin. After TGF-beta 1 treatment, the expression of alpha-smooth muscle actin increased and cells also expressed desmin. TGF-beta 1 at concentrations of 1.0, 5.0 and 10 ng/ml suppressed cell growth by 72%, 62% and 56%, respectively, downregulated SMemb/NMMHC-B mRNA expression by 71%, 52% and 38%, respectively and upregulated SM2 mRNA expression 2.1-, 3.0- and 5.3-fold, respectively. Conclusions. These results demonstrate that TGF-beta 1 modulates the smooth muscle cell phenotype from a proliferative to a contractile type and that the inhibitory effects of TGF-beta 1 on stromal cell growth correlate with downregulation of the SMemb/NMMHC-B gene.

    DOI: 10.1080/00365590500192918

    Web of Science

    PubMed

    researchmap

  • Mixed epithelial and stromal tumor of the kidney in a 12-year-old girl 査読

    N Hara, M Kawaguchi, S Murayama, R Maruyama, T Tanikawa, K Takahashi

    PATHOLOGY INTERNATIONAL   55 ( 10 )   670 - 676   2005年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BLACKWELL PUBLISHING  

    Mixed epithelial and stromal tumor of the kidney (MESTK) is a rare kidney neoplasm that almost exclusively occurs in perimenopausal women, and long-term estrogen replacement is relevant to its pathogenesis. Herein is described an atypical case of MESTK uncovered in a 12-year-old premenarcheal girl without a history of prior estrogen use. On surgical specimen it was found that the well-circumscribed tumor measuring 14 cm arose from the lower pole of the right kidney, showing solid and fibrous-cystic areas. Microscopically, it was composed both of epithelial structures similar to renal tubules and stroma comprising non-specific spindle cells. Some intratumoral tubules showed affinities to distal-nephron-specific lectins, and those immunoreactive for proximal-tubule-specific CD15 were also present. In addition, primitive ductal structures were reactive both for CD15 and lectins, but immature epithelial elements typical of nephroblastoma were absent. Spindle cells were positive for actin, desmin and vimentin, and expressed progesterone and estrogen receptors. The tumor was comparable with MESTK, although some epithelia were associated with the immunophenotype of proximal tubules. The patient was free of disease postoperatively for 40 months. In the present case, remnants of the primitive periductal mesenchyme might be promoted to neoplastic cells by a sex-steroid surge during puberty.

    DOI: 10.1111/j.1440-1827.2005.01888.x

    Web of Science

    PubMed

    researchmap

  • Angiomyxoid tumor with an intermediate feature between cellular angiofibroma and angiomyofibroblastoma in the male inguinal region 査読

    N Hara, M Kawaguchi, H Koike, T Nishiyama, K Takahashi

    INTERNATIONAL JOURNAL OF UROLOGY   12 ( 8 )   768 - 772   2005年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BLACKWELL PUBLISHING  

    Angiomyofibroblastoma (AMFB) and cellular angiofibroma (CA) are angiomyxoid tumors which infrequently arise in the female vulvovagina and each has been proposed to be a distinct clinicopathological entity. The former in male genitalia is exceedingly rare and has been described as its male analog or under the name of male AMFB-like tumor, while the latter in men has not been reported. We describe an angiomyxoid tumor which appeared in the inguinal region of 72-year-old man. The present case had a histopathological characteristic and immunophenotype intermediate between AMFB and CA. Male genital angiomyxoid tumors share many immunopathological features with their female counterparts, suggesting that they are male homologs rather than analogs. Immature mesenchymal cells with a potential of the multilineage differentiation might be promoted toward neoplastic myoblasts, fibroblasts and adipocytes, resulting in genital angiomyxoid tumors showing a broad spectrum in the immunopathological phenotype.

    DOI: 10.1111/j.1442-2042.2005.01148.x

    Web of Science

    PubMed

    researchmap

  • Placement of a urethral catheter into the ureter: An unexpected complication after retropubic suspension 査読

    N Hara, H Koike, Bilim, V, K Takahashi

    INTERNATIONAL JOURNAL OF UROLOGY   12 ( 2 )   217 - 219   2005年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BLACKWELL PUBLISHING ASIA  

    We describe an unusual complication caused by urethral catheterization which, to our knowledge, has not yet been reported. A 16 Fr urethral balloon catheter was unintentionally placed into the left ureter through the ureteral orifice in a 51-year-old woman following retropubic suspension surgery for stress urinary incontinence. After retrograde urography from the urethral catheter and removal of the catheter, reoperation was performed and a double pig-tail ureteral stent was placed in the left ureter with subsequent proper replacement of a urethral catheter. The patient had uneventful postoperative recovery. Although the presented accident was an unexpected complication which might be associated with anatomical changes resulting from colposuspension, we should have confirmed the catheter position intraoperatively.

    DOI: 10.1111/j.1442-2042.2005.01011.x

    Web of Science

    PubMed

    researchmap

  • Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer 査読

    N Hara, M Okuizumi, H Koike, M Kawaguchi, Bilim, V

    PROSTATE   62 ( 2 )   140 - 147   2005年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-LISS  

    BACKGROUND. The aim of this study was to visualize early stage prostate cancer (Cap) in a clinical setting. In previous studies, the results of magnetic resonance imaging (MRI) for screening Cap have rarely been confirmed by well-designed multisite prostate biopsy.
    METHODS. The prostate glands of 90 men with elevated prostate-specific antigen (PSA) were imaged by dynamic contrast-enhanced MRI (DCE-MRI) before transrectal ultrasound-guided 14-cores prostate biopsy. Each core was divided into three subcore fractions (total of 42 fractions) to generate a histological localization diagram, which was compared with localization-visualized DCE-MRI.
    RESULTS. The detection rate of Cap in 57 patients with PSA < 10.0 ng/ml was 36.8% as determined by the initial biopsy. DCE-MRI uncovered 92.9% of the clinically significant Caps and its specificity was 96.2% for the first biopsy session. One case with positive DCE-MRI and a negative primary biopsy was positive with additional biopsies. All of 26 DCE-MRI positive cases had significant Cap, and two of eight patients with histological Cap and negative or equivocal imaging had significant cancer. In total, 9 of 20 cases with DCE-MRI stage T2 underwent radical prostatectomy. All of them had organ-confined disease, although 33-77% (mean 63%) of them were expected to be rated T3 or higher by Partin's table.
    CONCLUSIONS. DCE-MRI can identify early stage Cap with high sensitivity and specificity, and can predict the histological grade to some extent. DCE-MRI prior to biopsy should be applied to younger patients with surgical indications. Otherwise, we recommend the definitive diagnosis of Cap by utilizing DCE-MRI alone. (C) 2004 Wiley-Liss, Inc.

    DOI: 10.1002/pros.20124

    Web of Science

    PubMed

    researchmap

  • Median raphe cyst in the scrotum, mimicking a serous borderline tumor, associated with cryptorchidism after orchiopecxy 査読

    N Hara, M Kawaguchi, H Koike, K Takahashi

    INTERNATIONAL JOURNAL OF UROLOGY   11 ( 12 )   1150 - 1152   2004年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BLACKWELL PUBLISHING ASIA  

    Median raphe cyst (MRC) is a benign lesion occurring predominantly in the ventral surface of the penises of young men and is an embryological developmental anomaly of the male genitalia. Serous borderline tumors (SBT) are found most frequently in the female ovary and only several cases with SBT of the male genitalia have been reported. We describe a case of MRC with features of SBT, which appeared in the scrotum of a 9-year-old boy after orchiopexy and was associated with surgery for cryptorchidism. The cyst arose on the right testicular tunica and consisted of cystic components with intracystic papillae lined by stratified epithelial cells, some of which showed mild cytological atypia and sporadic mitosis. These epithelial cells expressed CA 125, CA 19-9, carcinoembryonic antigen, estrogen receptor and progesterone receptor. Although no cases of MRC with characteristics of SBT in association with the rete testis has been described, the current report gives additional information for follow-up of cryptorchidism.

    DOI: 10.1111/j.1442-2042.2004.00965.x

    Web of Science

    PubMed

    researchmap

  • Application of serum PSA to identify acute bacterial prostatitis in patients with fever of unknown origin or symptoms of acute pyelonephritis 査読

    N Hara, H Koike, S Ogino, M Okuizumi, M Kawaguchi

    PROSTATE   60 ( 4 )   282 - 288   2004年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    BACKGROUND. Exclusion of prostatitis in screening for prostate cancer (Cap) is a matter of concern in the prostate-specific antigen (PSA) era. Yet, the identification of acute bacterial prostatitis (ABP), intentionally utilizing PSA in patients with pyrexia has been scarcely reported.
    METHODS. In total, 39 men, who presented at our department with a fever higher than 38.3degreesC, were randomly selected. We investigated the fraction of patients who had serum PSA levels higher than 4.0 ng/ml and categorized them according to an initial diagnosis of pyelonephritis, ABP, other urogenital infections, and fever of unknown origin (FUO).
    RESULTS. Six of nine cases initially diagnosed as pyelonephritis, presented with elevated PSA levels between 9.5 and 75.1 ng/ml. All six cases of clinically diagnosed prostatitis had PSA elevated between 4.1 and 13.6 ng/ml. In 8 of 18 FUO cases, PSA was elevated between 5.1 and 77.0 ng/ml. PSA levels significantly correlated with age (P < 0.005). All 20 patients with elevated PSA received antibiotics, and serum PSA was significantly reduced in all cases (P < 0.001) together with the alleviation of fever and normalization of CRP.
    CONCLUSIONS. PSA is a prompt and steady diagnostic tool for identifying ABP that might be missed or misdiagnosed. We recommend the measurement of PSA in cases not only with urologic infection but also puzzling pyrexia. (C) 2004 Wiley-Liss, Inc.

    DOI: 10.1002/pros.20077

    Web of Science

    PubMed

    researchmap

  • A case of ammonium urate urinary stone 査読

    Noboru Hara, Hiroshi Koike

    Acta Urologica Japonica   50 ( 5 )   351 - 353   2004年5月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    An 18-year-old female, who had undergone antireflux surgery for bilateral vesicoureteral reflux 5 years ago, was admitted to our department with complaints of fever and left-sided back pain. Bilateral renal stones and pyelonephritis were diagnosed after roentgenography, ultrasonography and urinalysis. Pyelonephritis was successfully treated with antibiotics and the left renal stone was completely disintegrated with extracorporeal shock wave lithotripsy. Spectrophotometric analysis revealed that the stone was composed of pure ammonium urate (AU). The patient had not experienced any episodes of urinary tract infection from the antireflux surgery until the present event, but had lost 20 kg in body weight during the last year due to a low-caloric diet and laxative abuse. AU urinary stones have been infrequently reported in Japan, and they are supposed to be associated with a low-caloric diet, laxative abuse, and anorexia nervosa.

    Scopus

    PubMed

    researchmap

  • Low-grade renal epithelial tumor originating from the distal nephron 査読

    N Hara, M Kawaguchi, H Koike, T Tsutsui, R Takagi, K Takahashi

    INTERNATIONAL JOURNAL OF UROLOGY   11 ( 2 )   68 - 73   2004年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BLACKWELL PUBLISHING ASIA  

    There are few published reports of low-grade renal epithelial tumor originating from the distal nephron. However, it should not be disregarded clinically, because the actual number of patients with such tumors may be higher than expected. We investigated the immunohistochemical profile of a histologically distinct subtype of such a tumor in detail, in addition to the clinical course and imaging studies. The present study demonstrated that both glandular and spindle cell components of this tumor have a persistent characteristic of an epithelial tumor arising from the distal tubule or collecting duct. This tumor is a benign complex neoplasm that can be treated successfully with radical surgery. Beta-catenin and E-cadherin are suggested to play a crucial role in tumorigenesis and the biphasic arrangement of this neoplasm, concerning the expression of epithelial membrane antigen and carbohydrate antigen 19-9. We suggest that the term 'distal nephron epithelioma' is appropriate for classifying such rare but clinicopathologically distinct tumors.

    DOI: 10.1111/j.1442-2042.2004.00754.x

    Web of Science

    PubMed

    researchmap

  • Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer 査読

    Motohiko Kimura, Toru Sasagawa, Yoshihiko Tomita, Akiyoshi Katagiri, Hideo Morishita, Toshihiro Saito, Toshiki Tanikawa, Takashi Kawasaki, Kazuhide Saito, Tsutomu Nishiyama, Takashi Kasahara, Noboru Hara, Kota Takahashi

    Acta Urologica Japonica   49 ( 12 )   709 - 714   2003年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    Seventeen patients were given lower dose and intermittent oral administration of estramustine phosphate (6 mg/kg/day) and etoposide (30 mg/m 2/day) for 7 days. Then administration was discontinued for 7 days. This administration cycle was repeated. Therapy was continued until evidence of disease progression or unacceptable toxicity occurred. Fifteen of the 17 patients were finally evaluated for PSA response. Overall, the pretreatment PSA levels were lowered at least 50% from baseline in 7 (47%) of the 15 patients. The median survival was 65 weeks. Five of the 17 patients complained of anorexia or nausea during the treatment, but none of them showed over grade 2 anorexia, none requiring transfusion or hospitalization. None of the patients showed edema, deep venous thrombosis, thrombocytopenia, anemia or myocardial infarction. Because of its rare and mild adverse effects, this intermittent administration of oral estramustine and oral etoposide may be a useful and secure regimen for hormone refractory prostate cancer.

    Scopus

    PubMed

    researchmap

  • Inducible nitric oxide synthase in renal cell carcinoma: Expression in tumor thrombi and induction under hypoxic conditions 査読

    N Hara, Bilim, V, T Kasahara, K Obara, K Saito, K Takahashi, Y Tomita

    ANTICANCER RESEARCH   23 ( 6C )   4641 - 4649   2003年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:INT INST ANTICANCER RESEARCH  

    Background: Nitric oxide (NO) has been suggested to have polar roles in carcinogenesis with both antitumor and tumor promoting activity, and the status of NO synthase (NOS) in renal cell carcinoma (RCC) has not yet been completely elucidated. Materials and Methods: We investigated the expression and induction of inducible NOS (iNOS) in RCC specimens and cell lines, respectively. Results: Although the expression of iNOS was not observed in primary lesions or in metastatic sites, it was found in 6 cases of 11 tumor thrombi. The cause-specific survival rate of patients with iNOS-positive tumor thrombi was lower than that of patients with iNOS-negative tumor thrombi, showing borderline significance. iNOS-mRNA and protein were expressed in A498 and A 704 RCC cells under hypoxic conditions. Conclusion: iNOS is suggested to be a significant molecule for RCC to acquire not only hypoxic adaptation but also the ability to invade into veins and form tumor thrombi.

    Web of Science

    PubMed

    researchmap

  • Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells 査読

    Y Tomita, Bilim, V, N Hara, T Kasahara, K Takahashi

    INTERNATIONAL JOURNAL OF CANCER   104 ( 4 )   400 - 408   2003年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-LISS  

    Caspases exist as zymogens, and are activated by various extracellular stimuli, leading to apoptosis. One such stimulus is Fas/CD95, a member of the tumor necrosis factor receptor family, providing one means of cytotoxic T lymphocyte (CTL)-mediated cell lysis. Clinical evidence has shown that administration of cytokine leads to regression in selected patients with renal cell carcinomas (RCCs). Interferon-gamma (IFN-gamma) indicates its contribution to anti-tumor activity of immune cells. IFN-gamma elicits its effect through the transcription factor signal transducer and activator of transcription-1 (STAT-1), and through interferon regulatory factor-1 (IRF-1), one of the target genes of STAT-1. Our previous study demonstrated an increase in the susceptibility of ACHN cells, established from RCC, to Fas-mediated apoptosis by IFN-gamma, and the inhibition of this effect by the caspase-3 and -7 inhibitor, DEVD-CHO. We demonstrated the following phenomena in IFN-gamma-treated ACHN cells: 1) enhanced transcription of caspase-1, 3 and 7 m RNAs without any change in cleavage of their substrates; 2) increased cleavage DEVD (specific for caspase-3 and 7), but not YVAD (for caspase-1) or DMQD (for caspase-3), after anti-Fas/CD95 MAb treatment; 3) activation of the STAT-1 and IRF-1 pathway; and 4) partial abrogation of the IFN-gamma-induced increase in Fas-mediated apoptosis by antisense IRF-1 oligodeoxynucleotide. These results suggest that IRF-1 plays a pivotal role in the IFN-gamma-mediated-enhancement of Fas/CD95-mediated apoptosis, through regulation of DEVD-CHO-sensitive caspases, most likely caspase-7. (C) 2003 Wiley-Liss, Inc.

    DOI: 10.1002/ijc.10956

    Web of Science

    PubMed

    researchmap

  • Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro 査読

    Bilm, V, T Kasahara, N Hara, K Takahashi, Y Tomita

    INTERNATIONAL JOURNAL OF CANCER   103 ( 1 )   29 - 37   2003年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-LISS  

    XIAP directly inhibits executor caspases, making it the most downstream antiapoptotic molecule. Here, we examined the expression and function of XIAP in normal urothelium and TCC. We also examined the therapeutic effect of xiap AS PODN on the cell cycle and apoptosis of multidrug-resistant T24 bladder cancer cells. XIAP was moderately expressed in normal transitional epithelium with prominent expression on the superficial layer cells. Seventy-nine of 108 (73.15%) tumor samples were positive for XIAP protein, but XIAP positivity was not correlated with tumor stage or grade. Moreover, 4 bladder cancer cell lines (SCaBER, HT 1376, T24 and RT4) expressed similar levels of XIAP. xiap AS PODN dose-dependently reduced the XIAP protein level and induced apoptosis, leading to decreased cell viability by 87%. Combined administration with doxorubicin resulted in marked cytotoxicity due to escalation of apoptosis. Overexpression of XIAP in T24 cells resulted in a modest but statistically significant (p < 0.01) survival advantage compared to parental cells. Thus, XIAP expression may be critical for maintaining the viability and drug resistance of TCC, and endogenous XIAP levels are sufficient to protect cells from apoptosis. Our results suggest that XIAP may play an important role early in human TCC carcinogenesis. xiap AS may be a candidate for use as a cancer therapy for overcoming drug resistance in highly malignant TCC. (C) 2002 Wiley-Liss, Inc.

    DOI: 10.1002/ijc.10776

    Web of Science

    PubMed

    researchmap

  • Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. 査読

    Hara N, Kasahara T, Kawasaki T, Bilim V, Obara K, Takahashi K, Tomita Y

    Clinical cancer research : an official journal of the American Association for Cancer Research   8 ( 6 )   1794 - 1799   2002年6月

     詳細を見る

  • A case of gas gangrene caused by colon diverticulitis with perforation into the retroperitoneal space 査読

    Masayuki Tasaki, Yoshiki Tsutsui, Ryo Maruyama, Noboru Hara, Shigenori Kurumada, Takeshi Komeyama, Norio Miyajima, Yoshihiko Tomita, Kota Takahashi

    Japanese Journal of Urology   93 ( 7 )   758 - 761   2002年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japanese Urological Association  

    We report a case of retroperitoneal gas gangrene, which was caused by cecal diverticulitis with perforation. A-57-year-old male was admitted to the Sado General Hospital with the chief complaint of right lateral abdominal pain. Roentogenogram and Computelized Tomography (CT) showed gas accumulation in the retroperitoneal space behind the ascending colon. Based on the clinical, labolatory, and instrumental examination findings gas gangrene was diagnosed. Since urolithiasis or urinary tract infection was suspected to be the cause of the lesion at that time. the patient was transferred to our department immediately. CT scan done on day 3 at our inpatient department provided data suspicious for the cecal perforation into retroperitoneal space due to appendicitis or diverticulitis. We performed an acute drainage of the abscess and intensive care including continuous hemodiafiltration (CHDF), oxygen under high pressure (OHP), and chemotherapy with antibiotics was carried out. However. in spite of the above mentioned measures, the patient's condition deteriorated and he died due to progression of gangrene and multiple organ failure in 23 days. The autopsy revealed that the cause of perforation was cecal diverticulitis. Retroperitoneal gas gangrene is an uncommon entity and has been rarely reported. It is supposed that laparotomy with diagnostic and therapeutic purpose should have been performed in this case.

    DOI: 10.5980/jpnjurol1989.93.758

    Scopus

    PubMed

    researchmap

  • Immunohistochemical studies of caveolin-3 in germ cell tumors of the testis 査読

    T Kasahara, N Hara, Bilim, V, Y Tomita, T Tsutsui, K Takahashi

    UROLOGIA INTERNATIONALIS   69 ( 1 )   63 - 68   2002年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:KARGER  

    Background/Aim: Caveolin, which is a major constructive component of the caveolar membranes, plays a key role in transcytosis of molecules into cells and regulation of several signal transductions. Caveolin has three isoforms, and recent studies suggest that in some malignant tumors an alteration of caveolin-1 expression correlates with oncogenetic changes. Caveolins have been reported to be negative regulators of inducible nitric oxide synthase (iNOS) which can provoke an antitumor response via infiltrating immune cells. The aim of this study was to examine the expressions of caveolin-1 and caveolin-3 (which is a caveolin-1 homologue localized predominantly in muscle tissue) in testicular cancer. Methods: We evaluated the expressions of caveolin-1, caveolin-3, and iNOS in 16 seminoma and 10 non-seminoma testicular cancer specimens as well as normal testicular tissue, using a streptavidin-biotin bridge technique on cryostat sections. The expression of caveolin-3 was confirmed by slot-blot analysis. Tumor-infiltrating immune cells were also studied immunohistochemically, and the correlation between the number of immune cells and caveolin-3 concentrations was calculated. Results: Immunohistochemistry revealed that caveolin-3, but not caveolin-1, was frequently expressed in seminomas (12 positive out of 16 specimens) without positive staining in their normal counterparts or in nonseminomatous germ cell tumors, except for muscle components in the teratoma. iNOS was not expressed in any tissues examined. Samples with high levels of caveolin-3 tended to have higher degrees of tumor-infiltrating immune cells, although this finding was not statistically significant. Conclusion: This is the first report demonstrating the involvement of caveolin-3 in germ cell tumors. Copyright (C) 2002 S. Karger AG, Basel.

    DOI: 10.1159/000064363

    Web of Science

    PubMed

    researchmap

▶ 全件表示

MISC

  • 4 HCG/FSH療法にて2児を得た男子低ゴナドトロピン性性腺機能不全症の1例(Ⅰ.一般演題, 第98回新潟内分泌代謝同好会)

    津田 晶子, 涌井 陽子, 荻原 智子, 原 昇

    新潟医学会雑誌   129 ( 2 )   94 - 94   2015年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • 15 前立腺癌根治療法前アンドロゲン抑制療法を行った患者のテストステロン値の推移(Ⅰ.一般演題, 第73回新潟癌治療研究会)

    武田 啓介, 山口 峻介, 結城 恵理, 原 昇, 西山 勉, 高橋 公太

    新潟医学会雑誌   128 ( 3 )   148 - 148   2014年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • 10 前立腺全摘症例におけるD'AmicoとUCSF-CAPRA(Cancer of the Prostate Risk Assessment)リスク分類の比較(Ⅰ.一般演題, 第72回新潟癌治療研究会)

    石崎 文雄, 西山 勉, 川崎 隆, 笠原 隆, 原 昇, 谷川 俊貴, 斎藤 俊弘, 北村 康男, アミヌール ホク, 赤澤 宏平, 高橋 公太

    新潟医学会雑誌   127 ( 11 )   638 - 638   2013年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    researchmap

  • 15 アンドロゲン除去療法に伴う骨代謝障害と同化ホルモン内分泌軸(下垂体-精巣軸, 下垂体-副腎軸, GH/IGF-1軸)の変化(I.一般演題, 第71回新潟癌治療研究会)

    石崎 文雄, 原 昇, 西山 勉, 伊佐早 悦子, 星井 達彦, 高橋 公太, 川崎 隆

    新潟医学会雑誌   126 ( 9 )   508 - 508   2012年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    researchmap

  • 16 前立腺癌アンドロゲン抑制療法による生体内アンドロゲン環境の変化と生物学的悪性度(I.一般演題,第70回新潟癌治療研究会)

    瀧澤 逸大, 西山 勉, 原 昇, 伊佐早 悦子, 星井 達彦, 高橋 公太

    新潟医学会雑誌   125 ( 3 )   169 - 169   2011年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • SY3-2 ABO血液型不適合腎移植"Translational Research"(3.腎移植の最前線,シンポジウム,第99回日本泌尿器科学会総会)

    齋藤 和英, 田崎 正行, 中川 由紀, 原 昇, 高橋 公太, 山本 格, 今井 直史, 西 愼一, 矢澤 伸

    日泌尿会誌   102 ( 2 )   2011年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-155 当院3年間の前立腺密封小線源療法の経験(前立腺腫瘍/放射線治療1,一般演題口演,第99回日本泌尿器科学会総会)

    白野 侑子, 瀧澤 逸大, 笠原 隆, 原 昇, 新井 啓, 西山 勉, 川口 弦, 青山 英史, 高橋 公太

    日泌尿会誌   102 ( 2 )   2011年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • PP-296 前立腺癌に対する組織内照射療法後の血清PSA値の推移に関する検討(一般演題ポスター発表・討論,一般演題ポスター,第99回日本泌尿器科学会総会)

    秋山 さや香, 笹本 龍太, 青山 英史, 瀧澤 逸大, 笠原 隆, 原 昇, 新井 啓, 西山 勉, 高橋 公太, 丸山 克也, 川口 弦

    日泌尿会誌   102 ( 2 )   2011年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • PP-285 アンドロゲン除去療法にともなう赤血球数の減少 : 成長ホルモン/インスリン様成長因子1(GH/IGF-1)内分泌軸と造血への影響(一般演題ポスター発表・討論,一般演題ポスター,第99回日本泌尿器科学会総会)

    原 昇, 伊佐早 悦子, 瀧澤 逸大, 星井 達彦, 石崎 文雄, 西山 勉, 高橋 公太

    日泌尿会誌   102 ( 2 )   2011年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • PP-539 前立腺全摘症例におけるD'AmicoとUCSF-CAPRAリスク分類の比較(発表・討論,一般演題ポスター,第99回日本泌尿器科学会総会)

    石崎 文雄, 高橋 公太, 西山 勉, 瀧澤 逸大, 笠原 隆, 原 昇, 谷川 俊貴, 斎藤 俊弘, 北村 康男, 川崎 隆

    日泌尿会誌   102 ( 2 )   2011年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-152 前立腺多数箇所生検に基づく癌の検出部位と全摘標本における精嚢浸潤との関連(前立腺腫瘍/診断・マーカー2,一般演題口演,第99回日本泌尿器科学会総会)

    田所 央, 小池 宏, 石崎 文雄, 原 昇, 川口 誠, 瀧澤 逸大, 西山 勉, 高橋 公太

    日泌尿会誌   102 ( 2 )   2011年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 17 前立腺癌におけるアンドロゲン抑制療法終了後のテストステロン値の回復についての検討(I.一般演題,第69回新潟癌治療研究会)

    星井 達彦, 西山 勉, 伊佐早 悦子, 原 昇, 高橋 公太

    新潟医学会雑誌   124 ( 3 )   176 - 176   2010年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • PP-553 腎細胞癌の転移再発とSerum Amyloid A (SAA)の検討(発表・討論,一般演題ポスター,第98回日本泌尿器科学総会)

    池田 正博, 西山 勉, 笠原 隆, 原 昇, 谷川 俊貴, 新井 啓, 小林 和博, 安楽 力, 高橋 公太

    日泌尿会誌   101 ( 2 )   2010年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-029 新潟大学における前立腺癌高線量率組織内照射療法 : 初期経験と線量分布改善のための工夫(前立腺腫瘍/放射線治療3,一般演題口演,第98回日本泌尿器科学会総会)

    笠原 隆, 西山 勉, 谷川 俊貴, 新井 啓, 原 昇, 池田 正博, 笹本 龍太, 丸山 克也, 高橋 公太

    日泌尿会誌   101 ( 2 )   2010年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-390 Trilostane, an Inhibitor of 3β-HSD, Has an Agonistic Activity for Androgen Receptors in the Prostate Cancer Cells

    西山 勉, 瀧澤 逸大, 星井 達彦, 笠原 隆, 原 昇, 高橋 公太

    日泌尿会誌   101 ( 2 )   330 - 330   2010年

     詳細を見る

    記述言語:英語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    DOI: 10.5980/jpnjurol.101.330_2

    CiNii Article

    researchmap

  • OP-090 ヒト前立腺癌培養細胞におけるカリクレイン発現についての検討(前立腺腫瘍/基礎1,一般演題口演,第98回日本泌尿器科学会総会)

    星井 達彦, 西山 勉, 滝澤 逸大, 原 昇, 笠原 隆, 谷川 俊樹, 高橋 公太

    日泌尿会誌   101 ( 2 )   2010年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • PP-186 アンドロゲン除去療法による骨代謝障害 : 成長ホルモン(GH)/インスリン様成長因子1 (IGF-1)/副甲状腺ホルモン(PTH)内分泌軸への影響(発表・討論,一般演題ポスター,第98回日本泌尿器科学会総会)

    原 昇, 伊佐早 悦子, 西山 勉, 瀧澤 逸大, 星井 達彦, 高橋 公太

    日泌尿会誌   101 ( 2 )   2010年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-404 前立腺癌アンドロゲン抑制療法による生体内アンドロゲン環境の変化と生物学的悪性度(前立腺腫瘍/薬物療法4,一般演題口演,第98回日本泌尿器科学会総会)

    瀧澤 逸大, 西山 勉, 原 昇, 伊佐早 悦子, 星井 達彦, 高橋 公太

    日泌尿会誌   101 ( 2 )   2010年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-363 Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)による前立腺癌診断 : Screeningと病期診断における有用性の評価(前立腺腫瘍/診断・マーカー5,一般演題口演,第97回日本泌尿器科学会総会)

    信下 智広, 小池 宏, 麻谷 美奈, 川口 誠, 原 昇, 高橋 公太

    日泌尿会誌   100 ( 2 )   2009年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-041 膀胱癌における転写因子ATBF1とp21(WAF1/CIP1)の発現 : 経過と予後の予測における有用性(尿路上皮/基礎,一般演題口演,第97回日本泌尿器科学会総会)

    原 昇, 川口 誠, ウラジミル ビリーム, 藤縄 勇治, 山本 修, 小池 宏, 高橋 公太, 三浦 裕

    日泌尿会誌   100 ( 2 )   2009年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-218 前立腺癌におけるアンドロゲン抑制療法終了後のテストステロン値回復についての検討(前立腺腫瘍/薬物療法5,一般演題口演,第97回日本泌尿器科学会総会)

    星井 達彦, 西山 勉, 伊佐早 悦子, 原 昇, 高橋 公太

    日泌尿会誌   100 ( 2 )   2009年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-217 アンドロゲン抑制療法後の血液中PSA値とアンドロゲン値の検討(前立腺腫瘍/薬物療法5,一般演題口演,第97回日本泌尿器科学会総会)

    伊佐早 悦子, 西山 勉, 原 昇, 星井 達彦, 瀧澤 逸大, 高橋 公太

    日泌尿会誌   100 ( 2 )   2009年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-460 腎細胞癌の再発予測におけるKattan Nomogramの有用性の検討(腎腫瘍/診断・マーカー,一般演題口演,第97回日本泌尿器科学会総会)

    鈴木 一也, 龍澤 逸大, 武田 啓介, 高橋 公太, 赤澤 宏平, 西山 勉, 原 昇, 谷川 俊貴, 水澤 隆樹, 新井 啓, 笠原 隆, 丸山 亮, 伊佐早 悦子

    日泌尿会誌   100 ( 2 )   2009年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • PP-082 前立腺初代培養上皮細胞のアンドロゲン代謝遺伝子発現の性状(前立腺/基礎2,一般演題ポスター,第97回日本泌尿器科学会総会)

    西山 勉, 原 昇, 鈴木 一也, 星井 達彦, 瀧澤 逸大, 高橋 公太

    日泌尿会誌   100 ( 2 )   2009年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 7 前立腺癌生検病理診断のISUPのコンセンサスに基づくGleason scoreの再評価と臨床的リスクに及ぼす影響(I.一般演題,第67回新潟癌治療研究会)

    若生 康一, 川崎 隆, 原 昇, 梅津 哉, 西山 勉, 内藤 眞, 高橋 公太

    新潟医学会雑誌   122 ( 4 )   225 - 225   2008年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟大学  

    CiNii Article

    CiNii Books

    researchmap

  • 11 無治療経過観察とした前立腺癌患者の検討(I.一般演題,第66回新潟癌治療研究会)

    原 昇, 斎藤 俊弘, 北村 康男, 小松原 秀一

    新潟医学会雑誌   122 ( 4 )   218 - 218   2008年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟大学  

    CiNii Article

    CiNii Books

    researchmap

  • APP-018 前立腺癌患者におけるアンドロゲン抑制療法の血中insulin-like growth factor 1に対する影響(前立腺癌/治療,総会賞応募ポスター,第96回日本泌尿器科学会総会)

    伊佐早 悦子, 西山 勉, 斉藤 俊弘, 原 昇, 笠原 隆, 高橋 公太

    日泌尿会誌   99 ( 2 )   2008年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-077 無治療経過観察とした前立腺癌症例 : 経過とMRI所見の検討(前立腺腫瘍/診断・マーカー4,一般演題口演,第96回日本泌尿器科学会総会)

    原 昇, 斎藤 俊弘, 北村 康男, 若月 俊二, 小松原 秀一, 西山 勉, 高橋 公太

    日泌尿会誌   99 ( 2 )   2008年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • APP-047 前立腺癌培養細胞における培養液内アンドロゲン環境変化によるアンドロゲン代謝酵素mRNAの発現量の変化(前立腺癌/基礎,総会賞応募ポスター,第96回日本泌尿器科学会総会)

    西山 勉, 原 昇, 笠原 隆, 瀧澤 逸大, 高橋 公太

    日泌尿会誌   99 ( 2 )   2008年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-163 当院における前立腺癌脊椎転移症例に対する放射線・手術治療(前立腺腫瘍/症例,一般演題口演,第96回日本泌尿器科学会総会)

    石崎 文雄, 笠原 隆, 原 昇, 谷川 俊貴, 西山 勉, 平野 徹, 土田 恵美子, 高橋 公太

    日泌尿会誌   99 ( 2 )   2008年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-303 内分泌併用放射線療法後のPSA推移の検討 : PSA再発をどのようにとらえるか(第95回日本泌尿器科学会総会)

    斎藤 俊弘, 原 昇, 北村 康男, 小松原 秀一

    日泌尿会誌   98 ( 2 )   2007年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • AVP-002 腎盂癌に対する経尿道的尿管引抜き術(第95回日本泌尿器科学会総会)

    北村 康男, 原 昇, 斉藤 俊弘, 小松原 秀一

    日泌尿会誌   98 ( 2 )   2007年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-243 腎細胞癌の増大速度の検討(第95回日本泌尿器科学会総会)

    伊佐早 悦子, 西山 勉, 北村 康男, 谷川 俊貴, 若月 俊二, 原 昇, 川崎 隆, 若生 康一, 高橋 公太

    日泌尿会誌   98 ( 2 )   2007年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-033 無治療経過観察 (WW) 前立腺癌患者における前立腺MRI(第95回日本泌尿器科学会総会)

    原 昇, 斎藤 俊弘, 北村 康男, 小松原 秀一, 関 裕史

    日泌尿会誌   98 ( 2 )   2007年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-213 泌尿器科開腹手術に対するに抗生剤の手術当日限定投与よる手術部位感染症(SSI)の検討(一般演題口演,第94回日本泌尿器科学会総会)

    北村 康男, 原 昇, 斉藤 俊弘, 小松原 秀一

    日泌尿会誌   97 ( 2 )   2006年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-029 患者体位を側仰臥位または側腹臥位とした尿管結石に対するESWL(一般演題口演,第94回日本泌尿器科学会総会)

    原 昇, 小池 宏, 斎藤 俊弘, 北村 康男, 小松原 秀一, 高橋 公太

    日泌尿会誌   97 ( 2 )   2006年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • MP-260 腎細胞癌におけるGalNAcDSLc4の発現と転移との関係(一般演題ポスター,第94回日本泌尿器科学会総会)

    丸山 亮, 冨田 善彦, 齋藤 誠一, ビリーム ウラジミル, 原 昇, 糸井 俊之, 山名 一寿, 西山 勉, 荒井 陽一, 高橋 公太

    日泌尿会誌   97 ( 2 )   2006年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • OP-276 当院におけるステージIII前立腺癌の治療成績 : 内分泌併用放射線療法の有用性(一般演題口演,第94回日本泌尿器科学会総会)

    斎藤 俊弘, 原 昇, 北村 康男, 小松原 秀一, 杉田 公, 松本 康男

    日泌尿会誌   97 ( 2 )   2006年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • MP-404 前立腺癌患者における末梢血PSA陽性細胞の動態(一般演題ポスター,第94回日本泌尿器科学会総会)

    大地 宏, 原 昇, 高橋 公太, 冨田 善彦, 吉田 淳子, ウラジミル ビリーム, 川村 裕子, 山辺 拓也, 内藤 整, 武藤 明紀, 加藤 智幸, 長岡 明

    日泌尿会誌   97 ( 2 )   2006年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 5 腎盂癌に対する経尿道的尿管引抜き術 : 術後の尿路上皮癌再発の検討(I.一般演題,第65回新潟癌治療研究会)

    北村 康男, 原 昇, 斉藤 俊弘, 小松原 秀一

    新潟医学会雑誌   119 ( 12 )   2005年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟大学  

    CiNii Article

    researchmap

  • 7 ホルモン依存性前立腺癌細胞LNCaPにおける副腎由来androgen代謝に対する考察(I.一般演題,第65回新潟癌治療研究会)

    鈴木 一也, 西山 勉, 原 昇, 山名 一寿, Bilim Vladimir, 糸井 俊之, 丸山 亮, 高橋 公太

    新潟医学会雑誌   119 ( 12 )   2005年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟大学  

    CiNii Article

    researchmap

  • 6 ステージD2前立腺癌の予後因子(I.一般演題,第65回新潟癌治療研究会)

    斎藤 俊弘, 原 昇, 北村 康男, 小松原 秀一

    新潟医学会雑誌   119 ( 12 )   2005年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟大学  

    CiNii Article

    researchmap

  • 前立腺癌診断におけるMRIを用いたPSA density の検討(第93回日本泌尿器科学会総会)

    星井 達彦, 原 昇, 西山 勉, 小松 集一, 若月 俊二, 谷川 後貴, 高橋 公太

    日泌尿会誌   96 ( 2 )   2005年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 腎細胞癌の自然経過の検討(第93回日本泌尿器科学会総会)

    利根川 悦子, 西山 勉, 原 昇, 谷川 俊貴, 若月 俊二, 高橋 公太

    日泌尿会誌   96 ( 2 )   2005年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 前立腺癌診断におけるPSA存在様式別、前立腺領域別PSA density の検討(第93回日本泌尿器科学会総会)

    小松 集一, 星井 達彦, 原 昇, 西山 勉, 高橋 公太

    日泌尿会誌   96 ( 2 )   2005年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • ホルモン環境の視点から考えたアンドロゲン抑制療法(第93回日本泌尿器科学会総会)

    西山 勉, 鈴木 一也, 山名 一寿, 原 昇, 若月 俊二, 谷川 俊貴, 高橋 公太

    日泌尿会誌   96 ( 2 )   2005年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • ホルモン依存性前立腺癌細胞LNCaPにおける副腎由来 androgen 代謝に対する考察(第93回日本泌尿器科学会総会)

    鈴木 一也, 西山 勉, 原 昇, 山名 一寿, Vladimir Bilim, 糸井 俊之, 丸山 亮, 高橋 公太

    日泌尿会誌   96 ( 2 )   2005年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • Utility of serum PSA to identify acute bacterial prostatitis in patients with pyrexia

    原 昇, 小池 宏, 荻野 宗次郎, 川口 誠, 奥泉 美奈, 高橋 公太

    日泌尿会誌   96 ( 2 )   250 - 250   2005年

     詳細を見る

    記述言語:英語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    DOI: 10.5980/jpnjurol.96.250_2

    CiNii Article

    researchmap

  • 当院における前立腺癌患者に対するRT-PCR法の有用性の検討(第93回日本泌尿器科学会総会)

    大地 宏, 吉田 淳子, 冨田 善彦, 原 昇, 高橋 公太, 長岡 明, 矢口 博理, 川村 裕子, 槻木 真明

    日泌尿会誌   96 ( 2 )   2005年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • PP3-116 前立腺Dynamic MRIと経直腸前立腺14ヵ所生検の検討(一般演題(ポスター))

    原 昇, 小池 宏

    日泌尿会誌   95 ( 2 )   2004年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • Expression of decoy receptor 3 in human urotherial cancer

    山名 一寿, ビリーム ウラジミール, 原 昇, 笠原 隆, 糸井 俊之, 新井 啓, 高橋 公太, 冨田 善彦

    日泌尿会誌   94 ( 2 )   2003年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • RT-PCRによる末梢血前立腺癌細胞の検出

    原 昇, 笠原 隆, ウラジミル ビリーム, 小原 健司, 糸井 俊之, 山名 俊之, 冨田 善彦, 高橋 公太

    日泌尿会誌   94 ( 2 )   2003年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 腎細胞癌におけるp14-arf遺伝子のhomozygous deletionの検討 : Real Time PCRによる定量的解析

    笠原 隆, Bilim Vladimir, 原 昇, 高橋 公太, 冨田 善彦

    日泌尿会誌   93 ( 2 )   2002年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 再燃前立腺癌に対するestramustin,etoposide併用間歇経口内分泌化学療法の多施設共同研究

    木村 元彦, 原 昇, 星井 達彦, 阿部 真樹, 高橋 公太, 冨田 善彦, 片桐 明善, 川崎 隆, 谷川 俊貴, 斎藤 和英, 西山 勉, 森下 英夫, 笠原 隆

    日泌尿会誌   93 ( 2 )   2002年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • ヒト前立腺間質培養細胞におけるTGF-betaによる細胞増殖抑制効果に対するSmad7の関与

    小原 健司, Vladimir Bilim, 小林 和博, 冨田 善彦, 原 昇, 笠原 隆, 新井 啓, 若月 秀光, 高橋 公太

    日泌尿会誌   93 ( 2 )   2002年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 前立腺癌診断における超音波造影剤使用経直腸超音波検査の有用性

    冨田 善彦, 高橋 公太, 原 昇, 車田 茂徳, 若月 俊二, 新井 啓, 谷川 俊貴, 笠原 隆, 斎藤 和英, 小原 健司

    日泌尿会誌   93 ( 2 )   2002年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 血清PSA値4.0以下の前立腺癌診断における経直腸指診の重要性

    田崎 正行, 原 昇, 笠原 隆, 若月 俊二, 谷川 俊貴, 車田 茂徳, 西山 勉, 冨田 善彦, 高橋 公太

    日泌尿会誌   93 ( 2 )   2002年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 腎細胞癌(RCC)における誘導型一酸化窒素合成酵素(iNOS)

    原 昇, Bilim Vladimir, 笠原 隆, 斉藤 和英, 小原 健司, 谷川 俊貴, 冨田 善彦, 高橋 公太

    日泌尿会誌   93 ( 2 )   2002年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • Adriamycin-triggered intracellular signalling resulting in apoptosis in RT4 bladder carcinoma cells

    ウラジミル ビリーム, 笠原 隆, 原 昇, 川崎 隆, 高橋 公太, 冨田 善彦

    日泌尿会誌   92 ( 2 )   253 - 253   2001年

     詳細を見る

    記述言語:英語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    DOI: 10.5980/jpnjurol.92.253_2

    CiNii Article

    researchmap

  • RT-PCRを用いた抹消血中circulating prostate cellsのdetectionによる前立腺癌の病期診断

    原 昇, 笠原 隆, ウラジミル ビリーム, 若月 俊二, 川崎 隆, 冨田 善彦, 高橋 公太

    日泌尿会誌   92 ( 2 )   2001年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 悪性リンパ腫を合併した腎細胞癌症例の検討

    糸井 俊之, 高橋 公太, 笠原 隆, 原 昇, 渡辺 竜助, 小原 健司, 若月 俊二, 木村 元彦, 谷川 俊貴, 冨田 善彦

    日泌尿会誌   92 ( 2 )   2001年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • Detection of AFP bearing cells in PBSC in advanced testicular cancer patients ; in vivo purging with multiple cycles of chemotherapy

    笠原 隆, 冨田 善彦, 原 昇, ウラジミル ビリーム, 高橋 公太

    日泌尿会誌   92 ( 2 )   299 - 299   2001年

     詳細を見る

    記述言語:英語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    DOI: 10.5980/jpnjurol.92.299_2

    CiNii Article

    researchmap

  • 腎細胞癌患者における周術期のLAK活性の変動とインターフェロン療法の可能性

    若月 俊二, 原 昇, 水澤 隆樹, 高橋 公太, 冨田 善彦, 川崎 隆, 糸井 俊之, 藤本 浩明, 有本 直樹, 谷川 俊貴, 小原 健司, 笠原 隆

    日泌尿会誌   92 ( 2 )   2001年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • Immunohistochemical detection ofcaveolin-3 in seminoma

    笠原 隆, Bilim Vladimir, 原 昇, 筒井 寿基, 高橋 公太, 冨田 善彦

    日泌尿会誌   91 ( 3 )   419 - 419   2000年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    DOI: 10.5980/jpnjurol.91.419_4

    CiNii Article

    researchmap

  • Caspase involved synergistic cytotoxicity of bcl-2 antisens phosphorothioate oligodeoxynucleotide and Adriamycin on Transitional cell cancer cell

    Bilim Vladimir, 笠原 隆, 原 昇, 高橋 公太, 冨田 善彦

    日泌尿会誌   91 ( 3 )   249 - 249   2000年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    DOI: 10.5980/jpnjurol.91.249_2

    CiNii Article

    researchmap

  • 系統的経直腸前立腺6カ所生検後の末梢血における前立腺特異抗原mRNA(PSAmRNA)産生細胞の存在についての検討

    原 昇, 笠原 隆, Bilim Vladimir, 川崎 隆, 高橋 公太, 冨田 善彦

    日泌尿会誌   91 ( 3 )   2000年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 細径シース,ループ,および内視鏡を用いた経尿道的膀胱腫瘍切除術および尿道狭窄部切除術の経験

    森下 英夫, 小池 宏, 内藤 雅晃, 原 昇, 有本 直樹

    日泌尿会誌   91 ( 3 )   2000年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 3)原発性アルドステロン症の1例( I. 一般演題, 第69回新潟内分泌代謝同好会)

    松石 泰三, 鴨井 久司, 佐々木 英夫, 原 昇, 小池 宏, 森下 英夫

    新潟医学会雑誌   113 ( 4 )   228 - 228   1999年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • 粘膜下子宮筋腫, 中隔子宮および子宮腔癒着症に対する経頚管的切除術の経験 : 第86回日本泌尿器科学会総会

    森下 英夫, 小池 宏, 原 昇, 中嶋 祐一, 鳥居 哲, 木村 元彦

    日泌尿会誌   89 ( 2 )   1998年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 腎細胞癌患者血清中の可溶性 CD95 (Fas/Apo-1) の予後規程因子としての可能性

    木村 元彦, 冨田 善彦, 片桐 明善, 谷川 俊貴, 今井 智之, 斎藤 俊弘, 原 昇, 高橋 公太

    日泌尿会誌   89 ( 2 )   1998年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 4)Mupirocin(抗MRSA鼻腔用軟膏)の使用経験(II. 一般演題 II, 第39回新潟化学療法研究会)

    森下 英夫, 小池 宏, 原 昇, 南波 乾次, 波多野 礼子, 佐藤 誠子

    新潟医学会雑誌   111 ( 12 )   788 - 788   1997年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • 4)新潟県における腎移植の現況(I. 一般演題, 第7回新潟外科系領域バイオメディカル研究会)

    筒井 寿基, 斎藤 和英, 片桐 明善, 米山 健志, 若月 俊二, 水澤 隆樹, 宮島 憲生, 原 昇, 星井 達彦, 谷川 俊貴, 武田 正之, 高橋 公太, 西 慎一, 上野 光博, 成田 一衛, 島田 久基, 荒川 正昭, 甲田 豊, 清水 武昭, 平澤 由平, 石川 暢夫, 唐仁原 全, 吉田 和清

    新潟医学会雑誌   111 ( 7 )   477 - 477   1997年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • Studer型回腸膀胱の尿管回腸吻合部狭窄に対するKTPレーザーによる尿管切開術

    玉木 信, 斎藤 稔, 原 昇, 〓木 立, 郷 秀人, 武田 正之

    日泌尿会誌   88 ( 2 )   1997年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

  • 逆行性前立腺全摘除術における神経温存手技の工夫

    玉木 信, 斎藤 稔, 原 昇, 擣木 立, 武田 正之

    日泌尿会誌   88 ( 2 )   1997年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本泌尿器科学会  

    CiNii Article

    researchmap

▶ 全件表示

受賞

  • European Urology, Reviewer of the Year, 2014

    2015年3月   欧州泌尿器科学会  

    原 昇

     詳細を見る

  • International Journal of Urology, Reviewer of the Year, 2012

    2012年4月   日本泌尿器科学会  

    原 昇

     詳細を見る

共同研究・競争的資金等の研究

  • 癌抑制因子ATBF1の細胞内局在をバイオマーカーとする膀胱癌悪性度診断法の開発

    2011年4月 - 2015年3月

    制度名:科学研究費補助金基盤研究C

    提供機関:日本学術振興会

    川口 誠

      詳細を見る

    資金種別:競争的資金

    researchmap

  • 転写因子ATBF1の前立腺癌細胞内局在の分子機構の解明と前立腺癌予後診断への応用

    2007年4月 - 2010年3月

    制度名:科学研究費補助金若手研究B

    提供機関:日本学術振興会

    原 昇

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

 

担当経験のある授業科目

  • 臨床検査実習

    2007年
    -
    2020年
    機関名:新潟大学